U Power Enters Macau Market; Signs of Its First Electric Service Provider (“ESP”) Agreement in Macau
UCAR has established various partnerships in Thailand, Portugal, Hong Kong, Peru and Mexico to jointly promote UOTTA battery-swapping services and are working on building a battery-swapping ecosystem in these markets
Full year 2024 total revenue was $6.2 million, representing an increase of 124% as compared to full year 2023
In 2024 UCAR sold and delivered a total of 12 battery-swapping stations
________________________
Hello Everyone,
Today’s profile jumped 25%. Continue to watch it.
We have a brand spanking new profile for tomorrow’s session. We are excited to get our hand on this one after looking at the chart.
It has been on the move north on extremely light interest.
This one looks thin!
Pull up UCAR for Tuesday.
U Power is a comprehensive provider of electric vehicle (EV) battery swapping solutions using its proprietary modular battery-swapping technology, UOTTA™. U Power manufactures and sells different models of UOTTA battery-swapping stations for EVs, and sells and rents battery swap cabinets to two-wheeled vehicle drivers. U Power also provides battery-swapping services for vehicle drivers and station control system upgrading services for battery-swapping station owners.
Through investments in next-generation technologies, U Power’s vision is to become a comprehensive solutions provider for smart energy grids. Expanding on its UOTTA technology platform, the Company is investing in building intelligent ecosystems that integrate resilient AI driven solutions able to transform electric vehicles (EVs) into dynamic energy assets.
U Power Enters Macau Market; Signs of Its First Electric Service Provider (“ESP”) Agreement in Macau
ESP Agreement to Facilitate the Deployment of UOTTA Battery-Swapping Stations and Sales of Four-Wheeled and Two-Wheeled Battery-Swapping Vehicles
SHANGHAI, June 30, 2025 /PRNewswire/ — U Power Limited (Nasdaq: UCAR) (the “Company” or “U Power”), a provider of comprehensive electric vehicle (“EV”) battery-swapping solutions with a vision of becoming a smart energy grid solutions provider, today announced the signing of its first agreement with an Electric Service Provider (the “ESP”) in Macau, aiming to facilitate the deployment and operation of U Power’s UOTTA battery-swapping stations and cabinets, as well as the sale of compatible electric vehicles (EVs).
Pursuant to the agreement, the local ESP will be responsible for the installation and maintenance of U Power’s UOTTA smart battery-swapping stations and cabinets in Macau. In addition, leveraging its existing partnership with UNEX EV B.V. (a Netherlands-based new energy and technology company which cooperates with OEM partners to design intelligent battery-swapping vehicles), U Power will work with the ESP to facilitate the sale and provide after-sale maintenance of compatible battery-swapping vehicles including four-wheeled passenger and commercial vehicles, and two-wheeled electric motorcycles, in the Macau market.
Over a three-year period, the ESP partner expects to be buying and then selling to the end users approximately 600 four-wheeled and 5,000 two-wheeled compatible battery-swapping vehicles, along with operating a corresponding number of battery-swapping stations and cabinets.
Johnny Lee, CEO and Chairman of U Power commented, “We are thrilled to announce U Power’s official entry into Macau via the signing of our first local ESP partnership agreement, a significant step forward towards establishing a battery-swapping ecosystem in this key market. We believe the ESP model will help us seize market share in Macau and we look forward to replicating this model in more regional markets including Hong Kong SAR and Singapore, thus accelerating U Power’s global expansion plan.”
UCAR is backed by strategic investor, Thai tycoon Chatchaval Jiaravanon a core member of the CP Group family and also one of Asia’s wealthiest families.
The CP Group is Thailand’s biggest conglomerate, based in Bangkok with businesses in telecommunications, finance, pharmaceuticals, automotive, food and retail.
The Jiaravanon Family manages a leading global industrial conglomerate and family office with a proven track record of managing more than $25Bln in assets, with over $82Bln in revenues and 450,000 employees. The Family’s holdings operate across 8 business lines, 14 business groups and 21 countries and economies.
Chatchaval Jiaravanon is executive director of the family’s Charoen Pokphand Group, also known as CP Group. Jiaravanon is also involved in C.P. Group’s technology, media and telecom businesses. He serves as a board member of Asian communications conglomerate True Corporation, which owns Thailand’s largest TV and Internet provider. In addition, he is chairman and founder of Charoen Energy and Water Asia; CEO of Charoen Pokphand Indonesia and is a member of INSEAD’s South-East Asia Council, among other roles.
In 2018, Chatchaval Jiaravanon purchased the Fortune media brand for $150 Mln in cash through Fortune Media Group Holdings Limited, set up as his personal investment company, independent of C.P. Group’s family businesses.
Why would this Thai Tycoon of Thailand’s biggest conglomerate back this tiny company?
U Power Limited (NASDAQ: UCAR) Announces Landmark Joint Venture with SUSCO, Targeting Thailand’s Multi-Billion EV Infrastructure Boom!
The importance of this deal cannot be over looked. The Thai Tycoon has plenty of money and experience to help launch this company and dwarf it into a massive global conglomerate.
Strategic Partnership to Address Rapid EV Growth Driven by Government Policy Changes in Thailand
U Power Limited (NASDAQ: UCAR), a world leader in rapid battery swapping technology for EV’s announced it has signed a joint venture agreement between its Thai subsidiary, U SWAP, and SUSCO Public Company Limited (BK: SUSCO), a publicly listed energy provider with a robust network of fueling stations throughout Thailand. The joint venture will deploy U Power’s innovative UOTTA battery-swapping technology across SUSCO’s extensive station network, significantly advancing sustainable transportation solutions in the country. The JV positions U Power as a first-mover in Thailand Commercial EV Battery Swapping Market.
“This joint venture represents a significant milestone in U Power’s global expansion strategy, particularly in Southeast Asia,” said Li Jia, Chairman and CEO of U Power. “Thailand’s ambitious EV targets make our partnership with SUSCO timely and strategically important, creating immediate oppor∙tun∙ities for scaling our battery-swapping technology across the region.”
Expanding EV Infrastructure with UOTTA Technology
SUSCO is a publicly traded energy provider listed in Thailand, recognized for its widespread network of fueling stations. By partnering with U Power, SUSCO aims to integrate battery-swapping capabilities into its existing infrastructure to meet the growing demand for electric vehicle (EV) energy solutions.
Through the joint venture, U Power’s UOTTA battery-swapping system will be strategically positioned at SUSCO’s fueling stations nationwide. This infrastructure will serve as a rapid, efficient, and scalable energy solution tailored to the needs of commercial vehicle fleets, including taxis and ride-sharing services, significantly reducing downtime and improving operational efficiency.
Integrating U Power’s innovative battery-swapping technology into SUSCO’s extensive station network allows SUSCO to directly support Thailand’s ambitious EV adoption goals, enhance customer convenience, and position SUSCO at the forefront of the nation’s evolving transportation infrastructure.
Leading Asian Investors Back Joint Venture with Strategic Investment
Chatchaval Jiaravanon, a member of the family controlling the Charoen Pokphand Group (CP Group)—a diversified conglomerate generating over $82 Bln in annual revenue—has personally invested in the joint venture between U Swap and SUSCO.
Mr. Jiaravanon currently serves as chairman and founder of Charoen Energy and Water Asia and independently owns Fortune magazine.
As highlighted in a recent press release, Mr. Jiaravanon expressed optimism regarding the significant potential for growth and pro∙fit∙abi∙lity of this partnership within Thailand’s rapidly expanding electric transportation sector. Leveraging his extensive financial and business relationships across the region, Mr. Jiaravanon is expected to create meaningful opportunities for U Swap’s accelerated growth.
Strategic Growth Aligned with Thailand’s Green Energy Goals
This partnership directly aligns with Thailand’s “30@30” policy, which mandates that 30% of new vehicle sales be electric by 2030. To accelerate this transition, Thailand’s National New Generation Vehicle Committee has prioritized infrastructure development through inve∙stment incentives, targeting the nationwide deployment of 12,000 charging piles and 1,450 battery-swapping stations by the policy deadline. Positioned at the intersection of government strategy and market demand, the joint venture is uniquely equipped to cap∙italize on these tailwinds and establish a dominant footprint in Thailand’s rapidly evolving EV ecosystem.
The agreement builds on U Power’s previous strategic collaboration with CP-MG, reinforcing the company’s systematic approach to market expansion and highlighting the trust major Thai corporations have in U Power’s battery-swapping technology.
Addressing Market Demand and Business Potential
Given Thailand’s significant taxi and ride-hailing fleet, currently exceeding 300,000 vehicles, battery swapping provides an attractive alternative to lengthy charging times. By deploying this technology within SUSCO’s extensive network, the partnership will directly address the practical challenges faced by high-utilization vehicles, boosting profitability and accelerating EV adoption.
“Thailand is entering a transformative period in electric mobility, and our partnership with SUSCO positions U Power at the forefront of this exciting transition,” said Li Jia. “Together, we aim not only to enhance Thailand’s green transportation infrastructure but also to establish a pro∙fit∙able and scalable model for other markets in Southeast Asia and beyond.”
About SUSCO
SUSCO Public Company Limited, a leading oil and gas retail company in Thailand, has been a key player in the energy sector since its establishment in 1981. Listed on the Stock Exchange of Thailand, SUSCO operates an extensive network of service stations across Bangkok and its surrounding areas, offering a wide range of products and services, including fuel retailing, aviation fuel supply, and CNG/LPG refueling.
SUSCO is renowned for its strong market presence and operational expertise, particularly in serving major international airports in Bangkok, including Suvarnabhumi and Don Mueang. In recent years, the company has actively pursued innovation and sustainability, exploring opportunities in electric vehicle charging, hydrogen fuel, and biofuel technologies to align with global energy transition trends. The partnership with U Power aligns perfectly with SUSCO’s commitment to leading Thailand’s transition toward sustainable energy solutions.
Through strategic partnerships, such as its collaboration with Sinopec (Hong Kong) Limited, SUSCO has expanded its footprint in Thailand’s retail fuel market and introduced new business models. With a proven track record of excellence and a forward-looking approach, SUSCO continues to solidify its position as a trusted energy solutions provider in Thailand and beyond.
U Power Provides Business Update and Outlines Key Objectives for 2025 and Beyond
Investing in Next-Generation Technologies with a Goal of Becoming a Smart Energy Grid Solutions Provider
SHANGHAI, June 10, 2025 /PRNewswire/ — U Power Limited (Nasdaq: UCAR) (the “Company” or “U Power”), a provider of comprehensive electric vehicle (“EV”) battery-swapping solutions with a vision of becoming a smart energy grid solutions provider, today provides an update of recent business developments, strategic partnerships and outlines its key growth initiatives for 2025 and beyond.
Recent Business Developments
– Expanded our client base and domestic footprint: Our proprietary UOTTA-powered battery-swapping stations and related solutions continued to gain traction. Our UOTTA technology offers fast, efficient battery swap for a variety of EVs including commercial trucks, buses, light trucks and passenger vehicles, including two wheeled and three wheeled. For full year 2024 we reported total revenue of $6.2 million, representing an increase of 124% as compared to full year 2023. During 2024 we sold and delivered a total of 12 battery-swapping stations.
– Established global partnerships: We have established various partnerships in Thailand, Portugal, Hong Kong, Peru and Mexico to jointly promote UOTTA battery-swapping services and we are working on building a battery-swapping ecosystem in these markets. We are partnering with major EV manufacturers in these markets to facilitate the sales of UOTTA-powered EVs and have begun delivering battery-swapping stations initially for taxi and ride-hailing services.
– Patents: We continued to strengthen our capabilities and introduced innovative UOTTA solutions supported by a large number of patents (46 issued patents and 18 pending patent applications).
Two-Fold Growth Strategy for 2025 and Beyond
Our key objective is to continue to grow our existing business, establish new business lines and generate additional revenue streams via a well-thought business plan based on two main pillars.
1. Leverage existing battery-swapping technology to build a comprehensive UOTTA-centered ecosystem. Specifically, we are:
Incorporating UOTTA into more EVs in our local market by taking advantage of the widespread adoption of EVs.
Accelerate international rollout via several partnerships we have established in Southeast Asia, Southern Europe and South America, and new ones we are targeting.
Continue investing in technology innovation and continuous upgrades of our one-stop UOTTA solutions.
2. Invest in next-generation technologies to develop comprehensive solutions for EV manufactures and drivers, aiming to transform EVs into dynamic assets for smart energy grids. Specifically, we plan to:
Continue investing in our AI-based data management cloud platform which connects UOTTA-powered EVs with stations and assists UOTTA-powered EV drivers locate the closest compatible UOTTA swapping stations on their route. Our continued investment aims to develop a comprehensive battery power solution platform which will offer advanced real-time data connections, analysis and forecasting capabilities, improve driving and re-charging experience, and serve as a complete urban road transportation solution.
Introduce “Battery Bank” solutions into the platform, aiming to enhance the performance of battery life cycle and use AI blockchain technology to monetize battery assets.
Introduce “Commercial Energy Storage” solutions for distributed and/or centralized energy storage stations, industrial and commercial EV charging and swapping stations, etc.
Johnny Lee, CEO and Chairman of U Power commented, “In early 2024 we made the strategic decision to re-organize and transform our business into a comprehensive solution provider for EVs, with a goal of becoming a smart energy grid solutions provider. The first step towards reaching our goal was the development of UOTTA battery-swapping stations and related solutions which reduce cost and timing of EV charging. Also, our UOTTA solutions are designed to minimize the need for extensive EV charging grid upgrades and facilitate the establishment of efficient and sustainable charging networks for the growing EV fleets of passenger cars or commercial trucks, which we are offering to both domestic and international customers. Our next step is to create a mature ecosystem by scaling up our UOTTA battery swapping operations, which will eventually enable and accelerate the development and implementation of new AI-based data management offerings and services such as Battery Bank business solutions, and Commercial Energy Storage solutions, transforming EVs into dynamic assets for smart energy grids.”
Mr. Lee added, “We believe our two-fold strategy has well-positioned U Power to grow revenue from existing business lines, create new revenue streams, improve profitability, expand client base and geographic footprint and ultimately create value for shareholders.”
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND FIVE HUNDRED USD BY SHORE THING MEDIA LLC FOR A ONE DAY UCAR AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Divestiture of the remaining 25.5% stake in FaZe Media eliminated $10 million in convertible debt from the balance sheet and approximately $2.5 million in quarterly cash burn
GameSquare’s largest investors are Dallas Cowboys owner Jerry Jones and the Goff family
First Quarter Revenues were $21.1 million, compared to $17.7 million the previous year
GameSquare to Develop Games for SpongeBob SquarePants through License Agreement with Paramount Game Studios
We have ran into some high flyers and fast movers over the past couple of weeks.
With the exception of one profile, we have seen just about everything else we profiled bear some fruit at one point or another.
We have a company on our radar for Monday that we haven’t taken a look at in a very long time.
Pull up GAME (GameSquare Holdings) right away and start your research on it.
GAME’s mission is to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Their next generation media, entertainment, and technology capabilities drive compelling outcomes for creators and maximize our brand partners’ return on investment. Through their purpose-built platform, we provide award winning marketing and creative services, offer leading data and analytics solutions, and amplify awareness through FaZe Clan, one of the most prominent and influential gaming organizations in the world. With one of the largest gaming media networks in North America, as verified by Comscore, they are reshaping the landscape of digital media and immersive entertainment. GameSquare’s largest investors are Dallas Cowboys owner Jerry Jones and the Goff family.
GameSquare Holdings Reports 2025 First Quarter Results
First quarter 2025 gross margin, excluding FaZe Media of 22.8%
Significant year-over-year improvement in first quarter 2025 adjusted EBITDA
Completed remaining divestiture of FaZe Media on April 1, 2025, which is expected to expand gross margin and eliminate approximately $2.5 million in quarterly cash burn going forward
Improved first quarter profitability in line with expectations and supports GameSquare’s strategic focus on achieving positive cash flow and adjusted EBITDA in 2025
FRISCO, TEXAS / ACCESS Newswire / May 15, 2025 / GameSquare Holdings, Inc. (NASDAQ:GAME), (“GameSquare”, or the “Company”), today announced financial results for the three-months ended March 31, 2025.
Justin Kenna, CEO of GameSquare, stated, “Our first quarter financial results were in line with expectations and reflect both the final quarter of FaZe Media’s impact on profitability and typical seasonal trends within our agency and programmatic advertising businesses. With the April 1, 2025 divestiture of our remaining 25.5% stake in FaZe Media, we eliminated $10 million in convertible debt from our balance sheet and anticipate an improvement in gross margin and reduction of over $2 million in quarterly operating expenses beginning in the second quarter of 2025. We continue to own 100% of FaZe Clan Esports, which contributed to revenue and was accretive to gross margin in the first quarter of 2025. As one of the top global esports teams, we are excited to capitalize on FaZe Clan Esports success and leverage the brand to drive profitable revenue opportunities.”
“Our SaaS business segment is well positioned for strong growth in 2025, driven by an expanded managed services offering and the integrated capabilities of the broader GameSquare platform. We are also seeing strong momentum in our creative agency business, particularly from successful world-building campaigns and in-person activations,” Mr. Kenna continued.
“As we continue to optimize our operating structure, achieving profitability remains a core objective of our 2025 strategy. In the first quarter, we significantly improved proforma, adjusted EBITDA from the same period a year ago reflecting a significant reduction in operating expenses. We expect to benefit from higher gross margin and additional cost-saving measures throughout the year. Based on the progress made in the first quarter, we believe we are on track to organically grow sales, and improve profitability in 2025 and beyond,” concluded Mr. Kenna.
Three months ended March 31, 2025, compared to March 31, 2024
Revenue of $21.1 million, compared to $17.7 million
Gross profit of $3.3 million, compared to $3.4 million
Net loss attributable to GameSquare of $5.2 million, compared to a net loss of $5.3 million
Adjusted EBITDA loss of $3.4 million, compared to a loss of $4.1 million
Adjusted EBITDA loss was 16.1% of revenue, versus 23.3% of revenue last year
Reported results for the three months ended March 31, 2025, compared to proforma* results for the three months ended March 31, 2024
Revenue of $21.1 million, compared to $23.5 million
Gross profit of $3.3 million, compared to $3.7 million
Operating expenses of $8.6 million, or 40.7% of revenue, compared to $11.6 million or 49.3% of revenue last year
Adjusted EBITDA loss of $3.4 million, compared to a loss of $7.9 million last year
Adjusted EBITDA loss was 16.1% of revenue, versus 33.7% of revenue last year
* Proforma financial results for the three months ended March 31, 2024, removes Complexity from GameSquare’s financial statements and includes a full quarter contribution of FaZe Clan
2025 Annual Guidance
Annual proforma revenue in 2025 between $100 million to $105 million
Annual gross margin of approximately 20% to 25% benefiting from a more profitable mix of revenue and the April 1, 2025, FaZe Media divestiture
GameSquare expects annual cash operating expenses in 2025 to improve by approximately $15 million from cash operating expenses in 2024 of $35 million, as a result the FaZe Media divestiture and a continual focus on reducing operating expenses and driving efficiencies
EBITDA and cash flow to improve throughout 2025 with positive EBITDA and cash flow in the second half of 2025
GameSquare’s Stream Hatchet Redefines Gaming Analytics with Breakthrough AI-Powered Data Ecosystem
Unmatched real-time intelligence and creator discovery tools position GameSquare at the forefront of AI-driven marketing wave
FRISCO, TEXAS / ACCESS Newswire / May 29, 2025 / GameSquare Holdings, Inc. (NASDAQ:GAME), a global leader in gaming and esports media, today announced the next evolution of its analytics platform. Stream Hatchet unleashes a revolutionary closed-loop data ecosystem powered by AI. Stream Hatchet’s newest innovation redefines how game publishers, global brands, and agencies connect with Gen Z and Millennial audiences across fast-growing, global live-streaming and social platforms like Twitch, YouTube, TikTok, and Instagram, among others.
Stream Hatchet’s proprietary system currently integrates data across 16 major live-streaming and social platforms, delivering real-time, actionable insights that empower clients like Capcom, Riot Games, Scopely, and Bungie to turbocharge campaign ROI, identify breakout creators, and drive authentic engagement with elusive youth demographics.
“This is more than an analytics upgrade. Stream Hatchet is reshaping the future of audience intelligence,” said Justin Kenna, CEO of GameSquare. “Our platform gives partners unprecedented clarity into audience behavior and influencer performance by putting the power of predictive, AI-powered decision-making directly into their hands.”
Tapping into a Projected $220 Billion AI Marketing Wave
According to a November 2024 release from ResearchAndMarkets.com, the global AI marketing analytics market is projected to surpass $220 billion by 2030 up from nearly $42 billion in 2023.
Breakthrough AI Tools Driving Precision Marketing
At the heart of Stream Hatchet’s opportunity is the company’s AI Discovery Tool that was launched in late 2024. This proprietary engine uses machine learning to decode creator content, audience sentiment, and engagement patterns-helping brands identify high-performing influencers and customize campaigns with surgical precision.
Stream Hatchet’s core innovation lies in its proprietary Individual Creator-Brand Affinity (ICBA) algorithm-an industry-first system that analyzes over 100 billion daily data points and seven years of historical engagement to match brands with the creators most likely to drive real-world conversions. Unlike conventional influencer platforms that rely on vanity metrics like follower counts, ICBA harnesses advanced Psychographic Profiling, Predictive Modeling, and Targeting at Scale to uncover deep behavioral and audience alignment. The result: unprecedented precision in identifying high-impact creators who authentically resonate with a brand’s values and target demographics-transforming influencer marketing from a guessing game into a data-driven growth engine.
Industry Momentum & Thought Leadership
Stream Hatchet continues to drive thought leadership with its 2025 Q1 Live Streaming Trends Report, reinforcing its role as the gold standard for performance benchmarking, influencer analytics, and trend forecasting across the $200 billion gaming economy.
With engagement spanning platforms like Twitch, YouTube, Kick, TikTok, and more, Stream Hatchet ensures clients are always one step ahead of the curve-anticipating trends, identifying breakout creators, and maximizing returns.
Join the Next Generation of Gaming Intelligence
GameSquare invites brands, publishers, and agencies to experience the future of gaming analytics with Stream Hatchet. Whether you’re optimizing a global campaign or launching a new title, our AI-powered platform gives you the tools to win in the attention economy.
About Stream Hatchet
A GameSquare company, Stream Hatchet is the global leader in real-time gaming and live-streaming analytics. Its AI-driven platform empowers publishers, brands, and agencies to unlock high-impact insights across streaming ecosystems and social platforms, bridging the gap between creators and commerce.
GameSquare to Develop Games for SpongeBob SquarePants through License Agreement with Paramount Game Studios
FRISCO, COLORADO / ACCESS Newswire / May 14, 2025 / Zoned, a GameSquare (Nasdaq:GAME) company, today announced that it has signed a license agreement with Paramount Game Studios to develop SpongeBob SquarePants-themed games in Fortnite.
“After an initial campaign in December 2024 that brought Bikini Bottom to thousands of fans and gamers, we are excited to expand our relationship with Zoned and GameSquare,” said Doug Rosen, Senior Vice President, Games and Emerging Media, Paramount. “We are excited to see what GameSquare and the team at Zoned can create and help more of our fans engage with their favorite SpongeBob SquarePants characters.”
“We are thrilled to deepen our relationship with Paramount, which is a testament to the success of our initial campaigns,” said Carlos Tovar, President of Zoned. “We’re excited to bring fun and creative SpongeBob SquarePants-themed games to global fans and gamers alike. We have an ambitious development plan, and we are looking forward to creating immersive games that highlight the very best of Bikini Bottom.”
This announcement follows a series of strategic partnerships secured by Zoned, a full-service marketing agency under GameSquare Holdingsthat specializes in bridging the gap between gaming and pop culture with the most recent launch of the Topgolf Universe on Fortnite’s UEFN platform.
**This is not sponsored, endorsed, or administered by Epic Games, Inc.
About Paramount Consumer Products
Paramount Consumer Products oversees all licensing and merchandising for Paramount (Nasdaq: PARA, PARAA), a leading global media and entertainment company that creates premium content and experiences for audiences worldwide. Driven by a diverse slate of consumer brands, Paramount Consumer Products’ portfolio is based on content from platforms including Paramount+, CBS (including CBS Television Studiosand CBS Television Distribution), cable networks (including MTV, Nickelodeon and Showtime), and Paramount Pictures. Additionally, the division operates Paramount Game Studios. With properties spanning animation, live-action, preschool, youth and adult, Paramount Consumer Products is committed to creating the highest quality product for some of the world’s most beloved, iconic franchises.
GameSquare’s Stream Hatchet Publishes 2025 Q1 Live Streaming Trends Report
Live streaming surges 9% year-over-year to 8.9 billion hours watched during the 2025 first quarter, reflecting the highest quarterly level since 2021
FRISCO, TX / ACCESS Newswire / April 24, 2025 / Stream Hatchet, the leading provider of data analytics for the live streaming and gaming ecosystem and wholly-owned subsidiary of GameSquare Holdings(NASDAQ:GAME), (“GameSquare”, or the “Company”), has released its Q1 2025 Live Streaming Trends Report. The report reveals key insights into the evolution of the global live streaming market across gaming, esports, and entertainment.
“Stream Hatchet’s 2025 Q1 report shows live streaming’s positive momentum as it remains one of the fastest growing forms of media and content globally,” said Justin Kenna, CEO of GameSquare. “Stream Hatchet’s reports continue to quantify the dramatic shift in how audiences are consuming media, reflecting trends to more interactive content and engaging experiences.”
Key Insights from Stream Hatchet’s 2025 Q1 Report:
1.
8.9 billion hours watched in 2025 Q1, reflecting the highest quarterly level since 2021
The report highlights a 9% year-over-year (YoY) increase in total hours watched across major live-streaming platforms, signaling continued growth in the industry despite shifting platform dominance.
While Twitch saw a 6.9% YoY decline, competitor platforms Kick (+112%) and YouTube Gaming (+25%) drove overall market expansion.
2.
Non-gaming content dominates
Non-gaming content emerged as the most-watched category, up 25.6% YoY, led by platforms such as Kick, Chzzk, and SOOP Korea, each recording ~94% YoY growthin the category.
Diversification underscores the broadening appeal of streaming as a mainstream content format.
3.
Esports remains resilient despite fewer events
While esports viewership dropped 2.3% YoY due to a reduced number of events, average viewership per tournament reached a five-year high, with major events like LCK Cup and Intel Extreme Masters contributing significantly.
4.
New platforms and languages shake up the ecosystem
The report also covers the shifting platform and language landscape:
Kick’s Arabic viewership grew by 491%, overtaking English as the platform’s top language.
Chzzk and Rumble joined the Top 10 platforms for the first time.
Facebook Live fell out of the Top 10, dropping 77% YoY in viewership.
5.
New game launches captivate audiences
Monster Hunter Wilds delivered the strongest day-one viewership of any title since early 2023 with 10M+ hours watched in its first 24 hours.
Meanwhile, Kingdom Come: Deliverance II and Schedule I broke into the Top 10 most-watched new titles, the latter boosted by heavy adoption among top Twitch streamers.
Experienced executive in gaming, esports, and media. Former CFO at FaZe Clan. Previously at Madison + Vine, Goldman Sachs, Deloitte, and Ernst & Young, and belongs to the Institute of Chartered Accountants.
LOU SCHWARTZ – PRESIDENT
Lou brings more than two decades of experience building and leading global digital technology and media companies, including founder and CEO of Multicast Media, CEO of Total Movie (UUX), and Chief Digital Officer at WWE. Lou is an internationally recognized speaker and expert in new media and monetization.
MICHAEL MUNOZ – CFO
Mike Munoz is an experienced finance executive with 15 years of experience in public accounting and corporate finance and 8 years serving as CFO of various public companies listed on the Nasdaq and TSXV.
TYLER BLEVINS – CIO
Tyler “Ninja” Blevins is one of the most recognizable gaming and entertainment personalities in the world. With more than 74 million fans worldwide on major digital networks, Tyler “Ninja” Blevins became a pop culture phenomenon in 2018, after he streamed on Twitch playing Fortnite alongside rappers Drake, Travis Scott, and Pittsburgh Steelers wide receiver Juju Smith-Schuster.
JOHN WILK – GENERAL COUNSEL
Mr. Wilk’s career spans an appellate judicial clerkship, tenure as a special counsel for Phillips Nizer in the practice areas of entertainment, intellectual property, and new media law, and two decades of experience as in-house counsel for media and technology companies.
MATT EHRENS – CTO
Technology & product leader with a proven track record for efficiently delivering versatile and valuable technical solutions to business challenges. Previously held leadership roles at Scripps Networks Interactive (now Warner Bros. Discovery), AARP, and AOL.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND THREE HUNDRED SEVENTY FIVE USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY GAME AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Nanoviricides, Inc. is close to having a single drug NV-387 for the treatment of all of the “tripledemic” respiratory viruses – Coronaviruses, RSV, and Influenza A, which would be a revolutionary achievement!
ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides, Inc has a more innovative approach that works even when viruses mutate
Hopefully you kept your feet moving as soon as you saw the news on today’s profile.
We think this next one has real potential both long and near term.
We have a fan favorite back int the crosshairs for tomorrow’s session. We have looked at this one a few times. We profiled this back in mid may at 1.40. Six sessions later it hit 10 month highs breaking through 1.90.
You might remember this one from January when it was sitting around the 1.10 level.
If you have been a member for a little while then you should go back and look at this one when we profiled it back last July when it doubled in just a few sessions.
Now that we have established that this one has the potential to move let’s dive into the meat and potatoes of what we want to look at for Fridays session.
Pull up NNVC and urgently get it on your screen.
NNVC looks well-positioned to be a market disruptor with nontoxic, effective antiviral therapies based on patented nanomedicine technology.
NNVC is a global leader in the application of nanomedicine technologies to the safe and effective treatment of viruses and their variants INCLUDING drugs against Covid-19, RSV and other respiratory viruses!
Even with a decline since 2022, COVID-19 continues to hospitalize and kill people in the USA – the CDC website states 69,200 hospitalizations and 2,652 deaths since January 1, 2024; the worldwide market size for COVID-19 therapeutics is expected to exceed $16.2 Billion in 2031.
NANOVIRICIDES are better because they destroy viruses and their variants without relying on the patient’s immune system, thereby making them effective for populations that include geriatric and pediatric patients.
Antibodies only bind by two points to the virus, and destruction of the complex requires effective immune function, which is not the case in sick patients..
Vaccines only train the body into producing antibodies against the virus in the vaccine. Antibodies and vaccines are easily overcome by viruses by mutating in the field, hence the need for annual influenza vaccine updates.
NV-387 – A novel broad-spectrum antiviral
Since it is a potential cure for RSV infection, and since there is no non-toxic drug for general treatment of RSV infection at present; NV-387 meets an unmet need.
A therapeutic for treating measles is a completely missing link in the response the the current measles virus outbreak; NV-387 could meet this unmet need too.
The anti-Influenza activity of NV-387 given orally was substantially superior to all three of the approved anti-influenza drugs (Tamiflu, Rapivab, and Xofluza).
Bird flu is rampant in poultry in the USA leading to hen culling and soaring egg prices, resulting in a race to find a treatment that works; NV-387 can address it.
Long COVID also remains a problem for an estimated 17 million adults; an effective antiviral such as NV-387 has already delivered successful Phase 1 results.
While smallpox is eradicated in the USA, contagious monkeypox has appeared but there is no effective drug treatment for it and competitors clinical trials have failed; NV-387 is entering Phase 2 clinical trials for it.
NanoViricides, Inc. (NYSE American: NNVC)’s lead drug candidate NV-387 (drug product NV-CoV-2), a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, NNVC has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.
Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.
Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have decades of effective usability against the target viruses similar to the life of current antibiotics against bacterial infections but in stark contrast to current antiviral approaches.
A broad-spectrum antiviral drug such as NV-387 would be a highly desirable drug globally because it would enable treatment by physicians of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of the drug.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Over 90% of human pathogenic viruses are known to use one or more “landing sites” that are in the Sulfated Proteoglycans (“SPG”) family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.
NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.
Superior to Other Treatments???????????
NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus, as reported earlier. We believe that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.
In treating Influenza, NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 “Bird Flu” as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.
NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin.
Moreover, even novel viruses, whether from natural sources or bio-engineered, are expected to be susceptible to NV-387 if they employ SPG for gaining access to human cells to infect and cause disease. Thus, NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics.
NV-387 could thus be a single drug to treat all of the “tripledemic” viruses (COVID, RSV, FLU ), and more, when so approved!
Finally, NV-387 was at least as effective as the approved drug tecovitrimat (TPOXX®, SIGA), in a lethal intra-digital infection by ectromelia virus in mice. Importantly, a combined drug made from NV-387 and tecovirimat was more effective than either drug alone, indicating NV-387 “plays well” with tecovirimat and acts by a different mechanism.
Smallpox poses a significant biodefense threat. Ectromelia virus is a native virus of mice in the poxvirus family and is one of the key animal model viruses for developing smallpox therapeutics. Tecovirimat is an approved drug for treating smallpox infection based on the FDA “Animal Rule”, and is stockpiled by the US “Strategic National Stockpile”. It was mobilized during the recent monkeypox epidemic.
It is important to develop additional smallpox therapeutics that work well with tecovirimat and by themselves, since viruses pose the threat of drug escape by mutation; further, in a bio-terrorism scenario, a human-engineered smallpox virus resistant to existing drugs could be a potential threat.
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa – Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu
NV-387 – Phase II Clinical Trial to Treat MPox Infection – Unmet Medical Need
We reported that we submitted requisite due diligence information to the National Ethics Committee of the Democratic Republic of Congo (DRC) including a draft report from the Phase I clinical trial for the safety and tolerability of oral formulations of NV-387, the summary information from our studies for treatment of lethal MPox infections in animal models, as well as summary information on the manufacturing.
The National Ethics Committee found that the provided information was sufficient to justify a Phase II clinical trial, and has cleared us to file a Phase II Clinical Trial Application for the Use of Oral NV-387 for the Treatment of MPox Disease Caused by the hMPXV virus, subsequent to the reporting period.
We also reported that we have commissioned manufacture of clinical trial quantities of NV-387 drug substance and the corresponding NV-387 oral gummies formulations drug products at our own cGMP compliant facility in Shelton, CT.
We are now preparing the Phase II Clinical Trial Application for NV-387 to combat MPOX for submission to the DRC regulatory agency.
There is no drug available for the treatment of MPox disease. The MPox Clade 1a/1b viruses have a substantially greater fatality rate than COVID, at 3-4%, and Clade 1b has been disproportionately affecting pediatric populations.
The MPox Disease which is caused by hMPXV Clade 1a/1b virus infection was initially declared a Public Health Emergency of International Concern (PHEIC) by the WHO in August 2024, a designation that has been continued to stay in effect in April 2025, due to the severity of the pandemic in WHO African Region.
Spillover cases of MPox Clade 1a/1b have occurred in several Eastern and Western countries already, raising the probability that the epidemic may spread more widely, although the current MPox virus is not as communicable as Coronaviruses or Measles virus.
MPox Clade 2 spilled over from Africa into the Western World in a small pandemic during 2022, and has become endemic with several cases occurring every year in many countries, driven primarily by sexual contact. MPox Clade 2 causes much less severe disease than the Clade 1a and 1b viruses.
MPox/Smallpox drug represents a billion dollar market globally, should an effective drug be developed, because of potential biosecurity implications.
NV-387 as Treatment for Measles Virus Infection – Unmet Medical Need
Upon finding significant rationale that NV-387 would be potentially highly effective against the Measles virus, we have initiated a program to evaluate NV-387 in a humanized animal model of Measles lethal infection.
The Measles outbreaks in the USA have continued to grow since January, 2025, and have crossed 1,000 confirmed cases as well as 3 deaths. Measles cases have been increasing year over year in the USA, especially after the COVID pandemic substantially resolved with the SARS-CoV-2 becoming an endemic virus. In Europe, over 35,000 cases of Measles have been reported in 2024 according to the European CDC.
A 95% vaccination coverage is required to eliminate Measles virus. This has become a practically impossible goal because of several factors, among them: (i) Vaccine Hesitancy as a rebound public response because of compulsion of COVID vaccine shots multiple times; (ii) Religious Vaccine Prohibitions in certain communities, including certain Jewish religious communities, Mennonites, and other conservative religious communities; (iii) Increasing immune function disability in the general population due to chronic diseases such as Diabetes, Obesity, Cardiac Issues, Autoimmune Diseases, Allergies, etc. wherein the person upon vaccination would not develop strong enough immunity and would become a carrier if infected; (iv) Vaccine Failure caused primarily by a variety of immune function disabilities.
The Measles vaccination rates across the world, and particularly in European countries and the USA have dipped well below 95% on average, and much lower in specific areas, and vaccine breakout cases i.e. Measles disease in vaccinated persons, have also increased substantially, as seen from the ECDC statistics [1] , [2] .
It is therefore essential to develop a drug to treat Measles in order to combat these outbreaks and achieve full control over the public health situation. There is no drug available for treatment of Measles.
We strongly expect that NV-387 would be effective against Measles. This is because NV-387 cured lethal RSV infection in an animal model. RSV and Measles both are paramyxoviruses, and both use HSPG as the Attachment Receptor, and then transfer to their respective Cognate Receptor that is needed for cell fusion. NV-387 was designed to present to the virus like a cell that displays HSPG-mimetic small chemical ligands on its surface, thereby providing the attachment-receptor-mimetic landing sites for the virus, capturing, engulfing, and destroying it. (HSPG = Heparan Sulfated Proteoglycans).
NV-387 as Treatment for Bird Flu, H5N1, H7N9 – Unmet Medical Need
We have previously found that NV-387 was substantially more effective than the existing stockpiled influenza virus treatments including Tamiflu (oseltamivir) and Xofluza (baloxavir) in lethal animal models of Influenza virus lung infection.
Given the extremely broad antiviral activity spectrum of NV-387, and knowing that the Highly Pathogenic Avian Influenza (HPAI) viruses such as H5N1 and H7N9 have polybasic sequences in their H-protein that bind to HSPG, we believe NV-387 would be effective against Bird Flu viruses.
Influenza viruses mutate rapidly, and also exchange their full genomic RNA segments with other co-infecting viruses (“Re-assortment”), or copy portions of a different genomic sequence into their own RNA (“Re-combination”). Thereby an Influenza virus can acquire new traits such as (i) rapid communicability from person-to-person, and (ii) readily escaping vaccines, antibodies, and the small chemical drugs such as oseltamivir and baloxavir.
NV-387, we believe, fulfills the unmet medical need for a pan-Influenza drug that the Influenza virus would not be able to escape, because the virus does not lose its ability bind to HSPG as Attachment Receptor and then to Sialic Acid Receptors leading to cell fusion and infection.
A severe version of H5N1 is widely circulating in the wild birds, and has caused sporadic losses of entire poultry farm houses. This, and a mild version of H5N1 have infected thousands of dairy herds in the USA. The H5N1 virus is only a few mutations away from becoming highly communicable from person to person, and if that comes to bear, we would be facing a pandemic possibly worse than COVID-19.
It is well established now that vaccines, antibodies, and small chemical drugs do not provide the ability to stall an outbreak let alone a pandemic caused by a highly variable virus such as a Coronavirus or an Influenza virus.
We believe NV-387 will be ready to fight any human outbreaks of H5N1 under emergency use protocols for investigational drugs.
Company Financials
We reported that, as of March 31, 2025, we had cash and cash equivalent current assets balance of approximately $2.73 Million. In addition, we reported approximately $6.98 Million in Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $1.20 Million.
The net cash utilized during the nine months ended March 31, 2025 was approximately $6.78 million. This included certain non-recurring expenditures including R&D expenditures in preparation for a Phase IIclinical trial application. We raised approximately $4.57 million net of commission and certain expenses in an At-the-Market offering (“ATM”) during the nine months ended March 31, 2025.
We have approximately $5.7 million (approximately $4.5 million net of current liabilities) available for cash operational expenses going forward including an available line of credit of $3 million provided by our founder and President Dr. Anil Diwan. As such, we reported that we do not have sufficient funding in hand to continue operations through February 14, 2026, for our planned objectives that include (i) a Phase II clinical trial of NV-387 for MPOX in Central Africa, (ii) a Phase II clinical trial of NV-387 for Viral Acute and Severe Acute Respiratory Infections (V-ARI and V-SARI), and (iii) Preparation and pre-IND filing for a Phase II clinical trial of NV-387 for RSV indication in the USA. We have access to the aforementioned ATM Equity Offering, and we believe we will have access to the equity markets to raise the funds necessary for our current objectives. We continue to re-prioritize our programs in line with available resources.
NV-387 – Phase I Clinical Trial Completed Successfully with No Reported Adverse Events
NV-387 has successfully completed a Phase Ia/Ib clinical trial in healthy subjects with all subjects discharged as of end of December, 2023. There were no adverse events reported. We are now awaiting a final report of this Phase I clinical trial.
NV-387 A Potentially Revolutionary Antiviral Drug that the Viruses are Unlikely to Escape
Our host-mimetic, direct-acting, broad-spectrum, antiviral agent. NV-387 was found to have activity that surpassed the activity of known agents in lethal virus infection animal model trials for COVID, RSV, Influenza, and Mpox/Smallpox.
In fact, we found that NV-387 treatment possibly completely cured the lethal RSV infection in mice, based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection. In particular, pediatric RSV infection treatment is an unmet medical need that we believe is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone.
NV-387 treatment was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche).
Additionally, NV-387 also demonstrated activity against lethal poxvirus infection animal models that was on par with or superior to the approved drug tecovirimat (TPOXX®, SIGA).
NV-387 acts by a mechanism that is significantly different compared to the tested existing antiviral agents for COVID, Influenza and Poxviruses.
This demonstrated broad-spectrum activity of NV-387 against widely varying viruses is because NV-387 is designed to attack the virus particle by mimicking sulfated proteoglycan (S-PG) feature, and all of these viruses are known to utilize heparan sulfate proteoglycans for gaining cell entry.
Further, for all of these tested viruses, even as the virus genome changes in the field, NV-387 is expected to continue to be effective, and the virus would be highly unlikely to escape NV-387. This is because despite all of the genomic changes, the virus continues to use HSPG, as is well known. Thus NV-387 solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all of the current antiviral tools that include vaccines, antibodies, and small chemical drugs.
Thus we anticipate that NV-387 would revolutionize the treatment of viral infections reminiscent of how penicillin revolutionized the treatment of bacterial infections.
NV-387 Regulatory Strategy
In the ensuing year, we plan on advancing NV-387 into Phase II clinical trials. In addition to the Phase II clinical trial to assess effectiveness of NV-387 in treating MPox infections, we are also planning to advance NV-387 into a Phase II clinical trial for treatment of Viral Acute Respiratory Infections (V-ARI), and Viral Severe Acute Respiratory Infections (V-SARI). This clinical trial is expected to provide information on NV-387 effectiveness in treating Influenza viruses, Coronaviruses (including SARS-CoV-2/COVID) as well as RSV.
Thereafter we are planning a regulatory program for advancing NV-387 as the treatment of pediatric RSV infection.
We plan on advancing the regulatory processes for NV-387 registration for other indications including Influenza and COVID via partnerships and non-dilutive funding.
As we meet the milestones, we believe we will be able to raise financing for further regulatory activities for NV-387 registration via non-dilutive grant funding, partnership revenues, as well as equity
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides’ Dr. Diwan
PUBLISHED
JUN 18, 2025 6:30AM EDT
SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), asserts that with new rising variants of COVID and Bird Flu, the single broad-spectrum antiviral drug NV-387 is well-positioned to support preparedness efforts and to combat potential pandemics.
Nimbus causes “razor-sharp” sore throat in some individuals, which is extremely painful and lingering for some time, in addition to the usual COVID symptoms.
Nimbus is more resistant to antibodies generated from previous vaccines, although prior vaccination or natural COVID infection is expected to still be protective in terms reduced severity compared to without such immunity according to CDC.
Nimbus is likely to be more transmissible than the previous variants. It belongs to the JN.1 subfamily of the Omicron family of SARS-CoV-2 virus.
Recently, the Influenza A H5N1 virus from a dairy worker in Michiganwas found to be capable of airborne transmission in a ferret animal model [1] (https://www.freep.com/story/news/health/2025/06/05/h5n1-bird-flu-michigan-dairy-farm-airborne-spread-cdc-study/84046550007/). This genotype B3.13 (clade clade 2.3.4.4b) virus in dairy cattle causes moderate severity disease in humans. In contrast, a highly pathogenic genotype D1.1 that is circulating in birds birds has led to one critical month-long illness in Canada and one death in the US signifying the potential for high morbidity and mortality from this genotype if it spreads in humans.
NV-387, the broad-spectrum antiviral drug is expected to be effective against all of these bird flu viruses. NV-387 was found to be substantially superior to Tamiflu® (Roche, Oseltamivir), Rapivab® (Biocryst, Peramivir), as well as Xofluza (Shionogi/Roche, baloxavir) in lethal lung infection animal model of Influenza infection. All three of these existing anti-influenza drugs are known to be escaped by Influenza viruses by single point mutations in H or PB2 genes.
NV-387 was found to be substantially superior to the approved drug Remdesivir in a lethal coronavirus lung infection animal model for SARS-CoV-2.
Thus the single drug NV-387 alone can combat H5N1, Influenza as well as COVID infections.
NV-387 has completed Phase I clinical trial in healthy human subjects with no reported adverse events.
COVID as well as Influenza viruses readily escape vaccines, antibodies as they change in the field during an epidemic wave. They are also likely to escape small molecule drugs by such changes.
NV-387 takes advantage of the invariant features that these viruses use for causing infection, by mimicking heparan sulfate-like structures. No matter how much these viruses change in the field, they continue to use the heparan sulfate attachment receptors in order to cause infection. Thus it is practically impossible that the viruses may be able escape NV-387 without losing their ability infect and transmit across humans, the Company believes.
NV-387 is orally available, formulated as oral gummies that dissolve in the mouth, thus avoiding issues of inability to swallow which occurs related to sore throat, old age, as well as in young children.
NV-387, as a treatment, is designed to help actually patients with disease recover rapidly, thus limiting the viral spread as well as providing for natural infection-based immunity in the recovered patient.
“NV-387 is thus the best current choice available for a highly cost-effective pandemic preparedness development,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “We have US-based cGMP manufacturing capabilities already set up as well.”
Of note, natural immunity, as induced by recovery from infection, is known to be superior to immunity from subunit and mRNA vaccines. One of the important reasons is that in natural infection, the immune system is subjected to all possible antigens from the entire virus, unlike just the selected antigens or antigen fragments that are present in subunit or mRNA vaccines.
Also, NV-387 can be manufactured in the USA and stockpiled readily at room temperature or refrigeration (for longer periods of time).
Unlike NV-387, vaccines or antibodies would require to be created after the virus takes hold, and they would suffer substantial loss of effectiveness within months after deployment due to changes in the virus. Additionally, vaccines require a cold chain handling. Vaccines also need to be administered to a large proportion of healthy population. There are significant logistical problems with vaccines. There is also the issue of vaccine reluctance, which is a personal choice, as it should be in a free country like the USA.
The broad-spectrum antiviral drug NV-387 was developed specifically to overcome all of these problems. In case of further spread of a severe COVID variant and also a Bird Flu variant in human populations, it will be possible to move NV-387 rapidly into Phase II clinical trial for these diseases, and then prepare for deployment early in the potential pandemic, curtailing its spread.
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo
SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”) today reported that it has received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP), of the Democratic Republic of Congo (DRC). With this CNES approval, the proposed Phase II clinical trial to evaluate safety and effectiveness of NV-387 for the treatment of patients with MPox disease caused by hMPXV infection is cleared for further regulatory filing of a complete Clinical Trial Application (“CTA”).
“We are now fully engaged in completing the detailed CTA for the Phase II human clinical trial of NV-387 for the treatment of MPOX disease (hMPXV infection) for submission to the DRC Regulatory Agency, namely MSP,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company.
The Company previously announced in January, 2025 that it has engaged a CRO for conducting a Phase II clinical trial to evaluate the safety and effectiveness of NV-387 for the treatment of MPox in the African Region.
Subsequently, the CRO has engaged the Medical Hospital at the University of Kinshasa as the clinical trial site (the “Site”) for the Phase II clinical trial.
Thereafter, the Company, the CRO, and the Principal Investigator at the Site have developed a package of information comprising synopses of the clinical trial protocol, and required background information on the novel drug NV-387, including a draft summary report of the Phase I human clinical trial, prior non-clinical data, as well as summary of the animal model effectiveness and safety of NV-387 for the treatment of lethal MPox infection providing rationale for the use of the novel broad-spectrum antiviral drug NV-387 for the treatment of hMPXV viral infection and the MPox disease caused by the infection.
This summary package was submitted to the National Regulatory Agency’s Ethics Committee CNES for a first review towards approval to proceed to the preparation and submission of the detailed CTA to the National Regulatory Agency, namely MSP of DRC.
The approval that we have now received from CNES clears the path for the perfected CTA filing to the MSP for approval and start of the clinical trial.
There is no drug available for the treatment of hMPXV infection that causes the MPox disease. A clinical trial of tecovirimat (TPOXX®, SIGA) failed to demonstrate any effectiveness over placebo, as per a NIH press release on August 15, 2024.
“NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases,” said Anil R. Diwan, Ph.D., adding “NV-387 is designed to mimic human cells to trap and destroy the virus. This single drug can target over 90-95% of human pathogenic viruses due to this biomimicry, which is reminiscent of the antibiotic penicillin that targets a large number of human pathogenic bacteria.”
NV-387 was found to be highly effective in increasing survival in lethal animal models of influenza virus, surpassing existing drugs Tamiflu®, Rapivab® and Xofluza® by a large margin.
NV-387 led to a complete cure of lethal RSV lung infection in an animal model study. There is no approved drug for RSV treatment.
NV-387 was found to be highly effective in increasing survival in lethal animal models of Coronavirus infection (a stand-in model for SARS-CoV-2 infection), surpassing existing drug remdesivir by a large margin.
NV-387 was found to possess strong antiviral activity against an orthopoxvirus in an animal model that is considered an important model to establish potential effectiveness against MPox and Smallpox viruses, as all of these viruses belong to the same family of orthopoxviruses.
In fact, NV-387 effectiveness matched the effectiveness of the small chemical drug tecovirimat in two different models of infection, one was direct skin infection, and the other was a direct lung infection, by the virus.
Escape of virus from tecovirimat can occur by a single point mutation in a viral protein called VP-37.
Vaccines, antibodies, and small chemical drugs such as tecovirimat for MPox/Smallpox, or oseltamivir (Tamiflu®), baloxavir (Xofluza®) for Influenza are readily escaped by viruses simply by introduction of small changes that viruses undergo when they are faced with these challenges in the field.
In contrast, escape of virus from NV-387 is highly unlikely because no matter how much the virus changes in the field, it continues to use sulfated proteoglycans such as HSPG as “attachment receptor” in order to cause cell infection. NV-387 mimics the sulfated proteoglycan signature feature that the viruses require.
MPox disease, caused by the human MPox virus (hMPXV) has been causing a regional pandemic encompassing several countries in the WHO African Region that includs the Democratic Republic of Congo (DRC), Uganda, and other countries. It led to the WHOdeclaring a Public Health Emergency of International Concern (“PHEIC”) on August 14, 2024. Since then, the PHEIC status declaration has been extended twice, most recently in March, 2025. The Mpox epidemic has continued to spread in the DRC, Uganda, and neighboring countries and the number of new weekly cases is still increasing in the WHO African Region.
NV-387 is a host-mimetic drug that “looks like a cell” to the virus, displaying numerous ligands that mimic the sulfated proteoglycan, enticing the virus to bind to and become engulfed by the NV-387 dynamic shape-shifting polymeric micelle.
Therefore development of NV-387, a broad-spectrum host-mimetic, direct-acting antiviral drug that the viruses cannot escape even as they change constantly, will be revolutionary once the drug undergoes regulatory development for approval for use in humans.
New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep appearing in time. To combat such threats, we need to develop broad-spectrum drug arsenal that the viruses cannot escape. Vaccines and antibodies simply will not do, and their limitations have become clearly evident during the COVID-19 pandemic.
Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.
He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)
interim Chief Financial Officer
Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.
Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
Randall W. Barton, PhD.Chief Scientific Officer – Consulting
Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.
Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.
Jayant Tatake, PhD.
Vice President, R&D
Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.
Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF THREE THOUSAND EIGHT HUNDRED FIFTY USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Today’s profile did not disappoint. It hit 2.42. Go back and take a look at how that one performed today.
We have an urgent potential bounce / squeeze situation you want to get on your radar ahead of the bell.
This one has been cut in half over the past two sessions, leading us to a great scenario in which we can research this one at historical bargain prices.
Pull up GVH Immediately.
Globavend Holdings Limited is an emerging e-commerce logistics provider, that formulates and implements integrated, end-to-end, cross-border logistics solutions for their customers with the provision of air freight forwarding services and related logistics services as their principal business. Their business model principally involves the provision of (i) integrated cross-border logistics services, which include air freight forwarding services offered as an integral part thereof; and (ii) air freight forwarding services, offered as a modularized logistics service segmented from our integrated cross-border logistics services. Their logistics network covers Hong Kong and four cities in Australia, namely Sydney, Melbourne, Brisbane, and Perth, as well as New Zealand.
Their integrated cross-border logistics services is our dominant business segment, which involve order processing, parcel consolidation, cross-border transportation (primarily by way of air freight), and air freight forwarding, followed by ground transportation and delivery at destination cities, together with other value-added services. While traditional logistics services providers typically provide fragmented logistics services and require customers to coordinate with various service providers, they, as an integrated cross-border logistics services provider, carry out the coordination with different players in the logistics value chain, including warehousing, customs clearance, and air freight or ground transportation services. This has effectively reduced the lead time and hassle and greatly improved the efficiency in fulfilling service orders. As an integral part of our integrated cross-border logistic services, we have also developed our own proprietary all-in-one shipping solution, which was modified by us internally on a shipping software purchased by us in 2019.
Their proprietary all-in-one shipping solution has been or can be connected to the internal sales or booking systems of customers, as well as the carrier management systems of the ground transportation carriers, to facilitate effective logistics management, the details of which are explained. Their services are provided primarily on a contract logistics basis, under which we provide our enterprise customers with customized integrated logistics services covering the entire delivery process.
Their services start by enterprise customers making errinstructions in their own internal sales or booking systems, which integrate into their own proprietary all-in-one shipping solution. Upon receipt of booking instructions, their services start and cover from order origination to the final point of sale or delivery without further efforts or coordination from customers. This service is a customized one so as to fit a customer’s own business model, representing a seamless combination of order processing, parcel consolidation, transportation, and delivery. For customers engaging our services with agreed price quotations, we can provide one-off or on-demand integrated cross-border logistics services. Alternatively, customers can also request for our logistics services on a modularized or one-off basis, i.e., they can request for any segment of our logistics services within the integrated cross-border logistics solution on a stand-alone basis. As part of our integrated cross-border logistics services, they also provide related logistics services, which include the provision of supporting transportation for freight forwarding purpose, storage of consignment, labelling of consignments, other related logistic services for freight forwarding purpose, freight management services via our proprietary all-in-one shipping solution, and delivery at destination.
They engage (i) air freight carriers for the provision of cargo spaces, (ii) supporting ground transportation companies for the ground transportation services in Australia and New Zealand, (iii) customs clearance companies in Australia and New Zealand for the preparation of freight documentation and arrangement for customs clearance, and (iv) local delivery service providers for dispatching and distributing our customers’ goods to their designated destination in Australia and New Zealand. Their integrated cross-border logistics services, together with their proprietary all-in-one shipping solution, enable them to provide efficient and customer-oriented services. This has resulted in their customers continuously engaging us for one-stop air freight forwarding services and comprehensive logistic services, allowing us to gradually build our customer base.
Globavend (Nasdaq: GVH) Reports FY2024 Net Income Growth of 24% Y/Y, Announces FY2024 Results
PERTH, AUSTRALIA, Feb. 12, 2025 (GLOBE NEWSWIRE) — Globavend Holdings Limited (“Globavend” or the “Company”) (NASDAQ: GVH), an emerging e-commerce logistics services provider, today announced its financial results for the fiscal year 2024. The Company has recorded a significant growth of 24% in its net income, marking a successful year for the organization.
“We are thrilled to announce our financial results for the fiscal year 2024, which reflect our commitment to delivering value to our customers and stakeholders,” said Frank Yau, CEO of Globavend. “Our strong net income growth is a testament to the hard work and dedication of our team, as well as our ability to adapt to the changing market conditions.”
Financial Highlights
Net income grew 24% year-over-year to $1.34 million
Earnings per share (“EPS”) grew 13% year-over-year to $0.09
Revenue of $16.5 million, representing a gross profit margin of 14.6%.
Globavend (NASDAQ: GVH) Inked Key Partnerships In Home Market Oceania As It Focuses On Footprint Expansion, Competing With The Likes Of FedEx and DHL
In an increasingly interconnected world where one’s customers are not only within their local market but can also be in different regions across the globe, the ability to efficiently deliver goods is critical. Globavend Holdings Limited (NASDAQ: GVH), an emerging e-commerce logistics provider offering end-to-end logistics solutions in Hong Kong, Australia and New Zealand, is entering the global logistics ecosystem, going against established players such as Deutsche Post AG (DHL) (OTC: DHLGY), FedEx Corp (NYSE: FDX) and Hongkong Post in delivering packages to the front door of awaiting individuals.
Globavend’s mission is to combine their experience, knowledge and network with flexibility and agility to provide a one-stop logistics solution to customers and enterprises. Founded in 2016, the company has grown over the years, becoming a premier service provider of end-to-end logistics solutions. While traditional logistics providers often offer a piecemeal service, requiring customers to coordinate with various service providers to fulfill delivery, Globavend takes ownership across the logistics value chain, including warehousing, customs clearance and air freight or ground transportation services.
The firm’s ability to undertake such ownership stems from its proprietary all-in-one shipping solution, which can be connected to the internal sales or booking systems of customers as well as the carrier management systems of ground transportation carriers to facilitate effective logistics management. Globavend reports that having this depth of control has enabled the firm to provide efficient and customer-oriented services to great success.
Globavend became a publicly traded company in November 2023, and in March 2024, the firm entered into a $20 million equity purchase agreement with Square Gate Capital Master Fund, LLC – Series 1. In both instances, the impetus behind these liquidity corporate actions was to bolster the firm’s capabilities by expanding warehouse capacity or elevating e-commerce logistics services into different verticals of the logistics supply chain.
Growth In E-Commerce Within Oceania
Within Oceania, specifically Australia and New Zealand, e-commerce has grown in recent years. As reported by the 2024 Australia PosteCommerce Industry Report, Australians spent approximately AU$63 billion (roughly $40 billion) online in 2023. With 8 out of 10 Australians shopping online during the year – which is estimated to be around 9.5 million households – the adoption of e-commerce is growing. E-commerce adoption is expected to continue growing, as the online share of retail spending was just 16.8% for the year; down from the 25% threshold attained during the COVID-19 period.
The growth in e-commerce is a key driver for the Australian freight and logistics market, which was estimated to be worth $89.78 billion in 2023 and is estimated to grow to $136.91 billion by 2032, based on research conducted by imarc. From a competitive standpoint, while multi-national firms such as DHL and FedEx are operators within the region, private logistic firms and governmental postal services are also competitive entities within the local logistical landscape.
Within this competitive landscape, Globavend’s value proposition is being a reliable one-stop shipping provider specifically designed for e-commerce businesses, with a lower price point than DHL and FedEx but providing comparable service quality in delivery. As noted by Research and Markets, the growth of the logistical landscape will continue into the foreseeable future, as factors such as the Australian government improving logistical infrastructure, a growing consumer base, rising exports and imports and increasing demand for products will broaden the ecosystem.
Globavend: Scaling For Operational Excellence
Globavend is taking the necessary actions to meet the expected demand for e-commerce from its key markets in the coming years. As outlined in its corporate presentation, the firm plans to take strategic action to strengthen its competitive position within the markets it operates in. An example of this is expanding its logistical services into different verticals of the logistics supply chain. Given that Globavend currently utilizes a network of service providers, its expansion plans include setting up ground transportation and customs clearance service teams. Furthermore, the firm plans to leverage technology to enhance its service offerings, namely, expanding parcel collection networks with smart facilities and providing 24/7 pickup, collection and drop-off services.
Attaining scale and a broad distribution network is essential for competitiveness within the logistics industry. To that end, Globavend plans to upgrade warehousing facilities for value-added logistics services and explore the formation of strategic alliances or acquisition opportunities.
Recently, the firm began partnering with NZ Post – a state-owned enterprise with the New Zealand Government as its sole shareholder – for last-mile delivery services. The company entered into a similar partnership with Australia Post, another state-owned enterprise that provides postal services across Australia. Apart from these, Globavend has also entered into a block space agreement with Australia’s largest airline, Qantas Airways. The airline carrier will provide Globavend with secured cargo space in its flights to and across Australia, thus allowing the firm to deliver products across the country more efficiently by leveraging the airline’s significant network.
Globavend, An Emergent Industry Leader
With e-commerce expected to grow in the future, Globavend is positioning itself to be a logistical leader and a top-of-mind choice for clients seeking to move their goods to individuals. The strategic actions the firm is undertaking to bolster its value proposition in the marketplace seek to enable the company to grow its market share and be a distinct operator relative to its industry peers.
Globavend Receives Government Non-Dilutive Grant Funding Approval
PUBLISHED
APR 28, 2025 7:00AM EDT
Approval-in-Principle Received For Up To $900,000 in Government Funding to Directly Support Globavend’s Expansion into the China Market
PERTH, AUSTRALIA, April 28, 2025 (GLOBE NEWSWIRE) — Globavend Holdings Limited (Nasdaq: GVH) (the “Company” or “Globavend”), an emerging e-commerce logistics provider, today announced that it has received approval-in-principle from a Hong Kong government administered business development grant. If approved, eligible companies may receive up to $900,000 non-dilutive grant funding and would be deemed irrevocably earned with no repayment obligations.
The approval-in-principle was given by the Dedicated Fund on Branding, Upgrading and Domestic Sales (BUD Fund), from the Government of Hong Kong, which was set up to support local businesses in scaling up their operations, modernizing infrastructure, and expanding into new markets. This funding program is to assist Hong Kong enterprise to capture the opportunities arising from China’s 12th Five-Year Plan. The Hong Kong Government has injected approximately US$770 million into the BUD Fund.
“The opportunity to quickly expand into the Chinese market marks a significant milestone for Globavend,” said Frank Yau, Chief Executive Officer. “We’re confident in our eligibility for funding and eager to use it to accelerate our expansion. We’ve already proven our model in Australia, New Zealand, and Hong Kong,” Yau added. “Adding China to that mix is a natural progression. With geopolitical tensions driving demand for alternative routes, Australia is emerging as a key logistics hub. Access to non-dilutive funding from the BUD Fund will help us scale without compromising our capital structure.”
Founder, Chairman of the Board and Chief Executive Officer
Over 15 years of experience in logistics industry
Prior positions include Regional Operations Manager (Asia Pacific) at DHL eCommerce Limited
Holds Bachelor of Science Degree in International Shipping Transport and Logistics and MBA from Hong Kong Polytechnic University and Chinese University of Hong Kong
Mr. Tsz Ngo Yu
Chief Financial Officer Appointee
Over 15 years of experience in finance, auditing, accounting, and corporate governance
Former audit manager at Deloitte Touche Tohmatsu
A member of the Certified Public Accountants Australia
A fellow member of the Hong Kong Institute of Certified Public Accountants
Holds Bachelor of Commerce Degree in Accounting and Finance and Master of Applied Finance from Monash University
Ms. San Man Leng
Independent Director Appointee and Chair of Audit Committee
Licensed CPA in California, member of American Institute of CPA.
Over 20 years of experience in accounting, auditing, business consulting, and corporate services.
Holds Bachelor of Arts degree in Business Economics from University of Southern California.
Mr. Ho Chuen Shin
Independent Director Appointee, Chair of Compensation Committee and Nomination Committee
Solicitor of High Court in Hong Kong with over 8 years of corporate practice experience
Advises companies and sponsors in IPOs and post listing compliance
A member of the Certified Public Accountants Australia
Holds Bachelor of Laws Degree and Postgraduate Certificate in Laws from Chinese University of Hong Kong
Mr. Fan Cheung
Independent Director Appointee
Over 13 years of experience in logistics, including international business expansion and corporate governance
Served at S F Express (Hong Kong) Limited, Deputy Director of Financial Planning
Chartered Secretary and Chartered Governance Professional
Holds Bachelor of Social Science degree, Bachelor of Laws degree, and Master of Corporate Governance degree
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SEVEN THOUSAND SIX HUNDRED TWENTY FIVE USD BY BEYOND MEDIA GROUP LLC FOR A ONE DAY GVH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
HUBC has secured contracts from ING, Boeing & Visa to name a few – Fortune 500 companies, startups, and government agencies are signing up for HUBC’s state-of-the-art cybersecurity solutions
HUB Cyber Security Wins €20 Million Contract to Lead Banking Modernization for Prestigious Financial Institution in Europe
HUBC operates in over 30 countries and provides innovative cybersecurity computing appliances as well as a wide range of cybersecurity professional services worldwide
HUB is acquiring BlackSwan Technologies, a leader in AI-driven secured data fabric solutions. This acquisition makes us a dominant force in data protection & compliance, powered by $50M of innovation. #CyberSecurity#DataFabrichttps://t.co/z8VKYsNXV9
Today’s profile was crazy. The dropped some heavy news that set off algorithms over 2 hours before the market opened. We saw it run all the way to 5.50, up over 100% on half a billion dollars in interest.
Moving onto another exciting situation quickly we wanted to turn your attention.
We have a past winner back on deck. This one just completed a 1 for 10 reverse back in March, drastically reducing the float.
Put HUBC on your screen for tomorrow.
High profile hacking incidents have shocked people around the world, showing them just how quickly things can turn bad if information is in the wrong hands. Information security firms are taking measures to protect customers and their own networks as they wait for official guidance following claims of a massive attack against Oracle Cloud in March. High-profile Chinese hacking incidents are also making cybersecurity a buzz worthy topic.The company specializes in unique cybersecurity solutions protecting sensitive commercial and government information and is a recognized leader in the rapidly evolving field of zero trust confidential computing, an area of cybersecurity that provides protection to data even when computers are infected, and administrators are compromised.
Over 500 customers including tier 1 customers such as Boeing, Visa, Lockheed Martin, BNP Paribas and more are choosing HUBC. The company has also secured two government contracts and won a $2 million contract with the Israel Airports Authority, showcasing its strategic growth within the cybersecurity domain.
HUB Security was established in 2017 by veterans of the elite intelligence units of the Israeli Defense Forces. The company specializes in unique cybersecurity solutions protecting sensitive commercial and government information. The company debuted an advanced encrypted computing solution aimed at preventing hostile intrusions at the hardware level while introducing a novel set of data theft prevention solutions. HUB operates in over 30 countries and provides innovative cybersecurity computing appliances as well as a wide range of cybersecurity professional services worldwide.
Delivers Essential Services To Global Blue-Chip Customers
120 experts specializing in Reliability Engineering, Safety, and Quality
300+ technology experts provide advanced software, testing, cybersecurity, and ICT services;
Comprehensive cybersecurity solutions to protect critical information and assets
In 2024, HUBC made significant strides in its strategic restructuring efforts, decisively closing underperforming businesses and optimizing its operations through targeted headcount reductions. The company believes these bold actions have transformed HUBC into a leaner, more agile organization, delivering tangible improvements in operational efficiency and setting a clear path toward sustained profitability.
The company’s products are already driving revenue growth, underscoring the market’s confidence in our solutions. Additionally, HUBC’srevitalized R&D team, led by the seasoned expertise of Mr. Nachman Geva, is accelerating innovation and ensuring that our offerings remain at the forefront of industry needs. HUBC is not just evolving—it is making real, impactful progress and optimizing every aspect of its business for a stronger, more dynamic future.
HUBC has successfully eliminated the majority of its high-cost debt, refinancing the business with long-term investors who share the company’s vision for sustainable growth.
These strategic actions are beginning to streamline HUBC’s liabilities and strengthen its balance sheet, providing enhanced financial flexibility to invest in high-growth opportunities, including the continued expansion of its Secured Data Fabric platform.
Big Data “Perfect Storm” Has Led to Data Fabric
AI generated data explosion – unprecedented volumes of data, overwhelming traditional systems
Cost efficiencies – legacy solutions are becoming prohibitively expensive to maintain and scale
Data silos and fragmentation – struggle with integrating diverse data sources
Need for real-time insights – businesses demand rapid access to insights
HUBC unifies all data, takes care of scalability, supports AI/ML, and is very cost-effective.
A unique platform featuring unbreakable, seamless, intelligent security
HUB’s SDF framework manages large volumes of sensitive data across diverse infrastructures, curring compliance and digital transformation costs by up to 50%
The SDF has already been successfully deployed in top European banks
Large pipeline of future customers across multiple industries
Unique synergies with IT services arm.
High software margins (+80%)
What is a Security Data Fabric?
Big data keeps getting bigger and security teams are struggling to leverage big data. This is because they have over a hundred security tools, often leading to millions of sensors that generate data in disparate and proprietary formats. Security Data Fabric helps to make sense of this data.
A security data fabric is a data fabric architecture that integrates and manages security data from various sources in a unified, secure, and governed approach.
HUB Professional Services
HUBC offers a broad portfolio of cybersecurity services and solutions worldwide, including managed services, compliance, and confidential computing. For over 30 years, HUB Security’s Professional Services division has protected information and assets for Fortune 500 companies, startups, and government agencies. Our state-of-the-art cybersecurity solutions are tailored to your industry, infrastructure, and applications, and include continuous risk assessments, ransomware resilience testing, incident response, and more. https://comsecglobal.com/
HUB Secure File Vault
About HUB Security’s Secure File Vault
HUB Security’s Secure File Vault represents a paradigm shift in data security. This innovative solution combines the power of a supercharged Managed File Transfer (MFT) system with dedicated hardware-driven security, creating a secure enclave to safeguard your organization’s data-driven workflows. In today’s business landscape, maintaining seamless digital interactions with customers, partners, suppliers, and subcontractors is fundamental. However, this continuous digital engagement also exposes organizations to the ever-increasing risks of cyberattacks and data breaches.
Why is the Secure File Vault Needed?
In an era where cyber threats and data breaches are on the rise, organizations must adopt innovative security solutions that not only simplify workflows but also protect sensitive data and ensure compliance with regulations. Despite extensive mitigation efforts, targeted data breaches remain a significant challenge, leading to financial losses, reputational damage, and legal complications. Traditional data protection mechanisms are often unable to keep pace with evolving threats. Secure File Vault addresses this pain point by providing a solution that surpasses the limitations of conventional MFT solutions.
How Does Secure File Vault Work?
Secure File Vault’s significance lies in its ability to provide an extra layer of security beyond traditional MFT solutions. It does so by integrating hardware-based secure enclaves into the data management process. These enclaves create controlled and isolated computing environments where data and applications are processed securely, shielded from unauthorized access, malicious actors, vulnerabilities, and network risks. This approach ensures data confidentiality and integrity even when the entire organizational infrastructure is compromised. HUB Secure File Vault Offers Several Unique Benefits:
Attack Surface Management – ASM
Consistently identify and address both your recognized and unforeseen external risks HUB Security’s Attack Surface Management provides you with insights into your genuine attack surface, encompassing the digital assets you acknowledge, those you might not be aware of, and any potentially harmful or unauthorized assets
What types of security issues can HUB Security identify in my external digital assets?
Certificate Authority issues
Compromised Credentials
Email Security issues
Exploitable Ports
Exposed Cloud Storage
Exposed Web Interfaces
Hijackable Subdomains
Mail Servers In Blocklist
SSL/TLS issues
Obtain the perspective of potential attackers!
To safeguard your organization, it’s essential to have a clear understanding of the assets and digital terrain requiring protection. While conducting vulnerability scans on known assets is straightforward, monitoring newly added assets within your infrastructure can be challenging.
HUBC’s Attack Surface Monitoring & Management offers automated, comprehensive insight into your digital footprint, revealing security concerns and vulnerabilities that could be targeted by potential adversaries.
Catalysts
Over 500 customers including tier 1 customers such as Boeing, Visa, Lockheed Martin, BNP Paribas and more! The Secured Data Fabric platform is the Company’s primary growth engine. This cutting-edge technology consolidates data from multiple silos into a unified, secure system that enables clients to navigate vast data pools, ensure compliance, and protect sensitive information with advanced encryption. HUBC’s solution stands apart from traditional data lake systems by securely retrieving data in real-time, offering a transformative approach that reduces costs and mitigates security vulnerabilities. This unique value proposition has driven strong demand, reflected in a significant increase in our backlog and a surge in RFPs from both existing and new clients. HUBC’s legacy IT services business provides a stable foundation with longstanding relationships across key sectors. The Company’s trusted advisor role to global enterprises enables HUBC to cross-sell its innovative solutions into these well-established accounts. It anticipates keeping a steady growth in the turnover and keeping the momentum in optimizing its margins. Recent achievements highlight HUBC’s growing influence and reliability in the market. In 2024, the company renewed partnership with a subsidiary of a major credit card service provider, securing a six-figure contract to enhance risk management and compliance measures. This demonstrates the company’s trusted role in safeguarding critical financial data. HUBC has secured two government contracts and won a $2 million contract with the Israel Airports Authority, showcasing its strategic growth within the cybersecurity domain. HUBC entered a landmark five-year agreement with Blackswan Technologies Ltd., a leading U.S. enterprise-AI vendor. This collaboration aims to provide state-of-the-art transaction monitoring and cyber risk mitigation solutions for a top-tier European bank, reflecting the company’s strategic expansion into the finance sector. Financially, HUBC is on solid ground. In April 2024, the company successfully secured $8 million through a straight debt financing arrangement. This influx of capital supports HUB’s strategic investments and growth initiatives. Most recently HUBC successfully restructured $7 million, more than 60% of its secured debt. Ms. Renah Persofsky, ICD.D. has been made the company’s new Active Chairperson of the Board of Directors, effective from March 25, 2025. Ms. Persofsky also serves as Executive Chair of Green Gruff, a pioneer in sustainable pet wellness products, and Vice-Chair of Tilray Brands, a leading global cannabis lifestyle and CPG company.HUBC’s client base includes high-profile names such as Rafael Advanced Defense Systems, the developer of Israel’s ‘Iron Dome,’ underscoring the company’s capability to deliver critical security solutions at a national level. The company’s commitment to excellence and innovation continues to drive its success and market expansion.
High Profile Chinese Hacking Incidents Have Made Cybersecurity a Buzz Worthy Topic Again!
The “Salt Typhoon” Chinese hacking incident in 2024, which targeted U.S. telecom companies, could drive higher spending on cybersecurity says one analyst.
Salt Typhoon is the name given to a Chinese hacking group that has compromised at least nine U.S. telecommunications firms, reportedly hacked into the phones of President-elect Donald Trump and Vice President-elect JD Vance and collected geolocation data for hundreds of phones based around Washington D.C.!
Atop federal cybersecurity official said in January 2025 that threat hunters from the Cybersecurity and Infrastructure Security Agency first discovered activity from Salt Typhoon on federal networks, allowing public and private sector defenders to more quickly “connect the dots” and respond to Chinese attacks on the U.S. telecommunications industry.
These attacks have occurred despite the Biden administration worked to improve communications with China!
You may remember in the early hours of July 19; a well-known cybersecurity company CrowdStrike (CRWD) published a faulty software update that temporarily disabled more than 8.5 million PCs that use its services. This chaotic outage resulted in problems across banking, health care and many other industries.
What the outage also did was bring more awareness to just how important cybersecurity is and to the potential value of cybersecurity stocks.
U.S. policymakers and the private sector are now faced with the challenge to secure the best cybersecurity solutions. U.S. regulators and lawmakers are even proposing new rules to protect hospitals from cyberattacks in 2025 after a bruising year of hacks and software outages.
According to current projections, the cybersecurity market is expected to reach a value of approximately $403 billion by 2027, highlighting the significant growth and increasing demand for robust cybersecurity solutions as cyber threats evolve rapidly.
Key points about this prediction:
Market Expansion:
This substantial growth is driven by the growing reliance on digital systems across industries, making cybersecurity a crucial priority for businesses and organizations.
Outsourcing Trend:
A significant portion of this value is anticipated to come from the cybersecurity outsourcing market, where companies increasingly seek external expertise to manage complex security challenges.
Evolving Threats:
The ever-changing landscape of cyber threats, including sophisticated ransomware attacks and advanced persistent threats, is further fueling the demand for advanced cybersecurity solutions.
HUB Cyber Security Wins €20 Million Contract to Lead Banking Modernization for Prestigious Financial Institution in Europe
TEL AVIV, Israel, April 09, 2025 (GLOBE NEWSWIRE) — HUB Cyber Security Ltd. (NASDAQ: HUBC) (“HUB” or the “Company”), a global provider of cybersecurity and data protection solutions, today announced it has been selected by Cassa di Risparmio della Repubblica di San Marino S.p.A. (the “Bank”) to execute a comprehensive €20 million digital banking and infrastructure modernization initiative (the “Project”). The Bank is the oldest financial institution in San Marino. The Project remains subject to regulatory approvals and the execution of a definitive agreement. Subject to the foregoing, HUB expects to implement the Project by the end of 2025.
HUB’s secure, on-premise infrastructure model was chosen for its strategic alignment with San Marino’s evolving regulatory landscape, coupled with its cost-effective, OPEX-driven financial approach. This landmark initiative aims to revolutionize the Bank’s core technology ecosystem — encompassing regulatory compliance, advanced cybersecurity, data center modernization, and a full overhaul of its core, mobile, and online banking platforms – using HUB’s secured data fabric solution.
Noah Hershcoviz, CEO of HUB, stated: “We are honored to be selected by this prestigious European financial institution to lead its transformative initiative. This contract represents a key milestone in HUB’s strategic expansion into the regulated banking sector, reinforcing our position as a trusted partner in high-security, mission-critical environments. We view this as a long-term growth opportunity and look forward to delivering sustained value through innovation, operational excellence, and deep regulatory alignment.”
This multi-year agreement provides continuous AML and KYC monitoring for up to 1.5 million customer entities, as well as specialized RegTech integration services
TEL AVIV, Israel, June 18, 2025 (GLOBE NEWSWIRE) — HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”), a leading provider of AI-driven compliance technology and core banking platforms, announced today the signing of a perpetual KYC and compliance services agreement with Kyrrex, a global crypto ecosystem and digital asset exchange, jointly with a large crypto merchant vendor, serving as a premier cryptocurrency payments gateway, in connection with the planned merger between Kyrrex and the crypto merchant vendor (the “Agreement”).
Under the Agreement, HUB will deliver its flagship Perpetual KYC (“PKYC”) solution, which features continuous, automated monitoring, management and verification of customer identities, along with horizon scanning regulatory intelligence, automated risk scoring, and data fabric based integration services. The PKYC engagement under the Agreement is priced according to an annual recurring basis and is anticipated to cover approximately 1.2 million to 1.5 million customer entities, translating to around US$25 million in recurring annual revenue for HUB, commencing on July 1, 2025.
The Agreement also provides HUB-led “Regulatory Readiness Sprints” during pre-close due diligence, the rollout of a Unified KYC Secured Fabric for day one cost synergy capture, and ongoing Horizon Scanning-as-a-Service to keep the merged entity well ahead of evolving MiCA, FinCEN, and FATF requirements.
“This Agreement reinforces HUB’s position as a mission-critical partner for companies operating at the intersection of compliance and growth,” said Noah Hershcoviz, Chief Executive Officer of HUB. “Kyrrex and the crypto merchant are assembling a category-leading crypto services platform, and the Company’s AI-native technology will deliver real-time customer intelligence and regulatory adaptability from day one. The Agreementadds a high-margin recurring revenue stream to HUB’s portfolio, supporting our long-term growth and profitability objectives. It serves as a prime example of how HUB turns regulatory friction into strategic advantage.”
About Kyrrex
Kyrrex is a Malta-based fully regulated crypto fiat ecosystem that provides a one-stop shop for bridging finance, payment, and trading operations with cryptocurrency on a single platform. Kyrrex holds a Class 4 Virtual Financial Assets (VFA) license and is transitioning to full MiCA compliance as well as actively pursuing Electronic Money Institution (EMI) and MiFID authorizations. These additional licenses will allow Kyrrex to offer clients an integrated, one-stop-shop platform, combining digital banking services with access to traditional financial markets, such as equities, commodities and foreign exchange, as well as regulated crypto derivatives.
About the Crypto Merchant
The Crypto Merchant operates one of the world’s longest-running crypto payment gateways, supporting merchants in over 190 countries across the globe.
Mr. Noah Hershcoviz joined HUB Security as the Chief Strategy Officer and became a member of the company’s Board of Directors on October 4, 2023. Noah Hershcoviz brings a wealth of financial and execution expertise, with a background that includes roles in the M&A division of Ernst & Young (EY) and as an investment banking executive in various capacities. He boasts a distinguished track record of managing investments and consistently exceeding market performance benchmarks. With a proven history of successfully guiding companies through initial public offerings, mergers and acquisitions, and reverse takeovers, Mr. Hershcoviz embodies an entrepreneurial spirit coupled with a global perspective on business transformation. His leadership is expected to play a pivotal role in charting the vision and strategic direction of the company, bringing innovative and industry-leading approaches.
Osher Partok Rheinisch
Chief Legal Officer
Osher Partok Rheinisch has more than 20 years of commercial, corporate and compliance legal experience. She was admitted to both the Israel and the New York State Bars and is a member of the Association of Corporate Counsels and the International Association of Privacy Professionals where she holds CIPP/E, CIPM and FIP authorizations. Prior to joining HUB Security, Osher was the General Counsel at Orgenesis (NASDAQ: ORGS) and the Compliance Counsel of Amdocs (NASDAQ: DOX). Osher holds an LLB and an MBA from Tel Aviv University.
Nir Bar-Eli
CEO of Comsec Global
Mr. Bar-Eli has over 20 years of experience managing sales organizations for large companies. Before becoming Comsec’s CEO, Mr. Bar-Eli served as the CEO of Comsec Distribution Ltd., another of the Company’s subsidiaries, since 2014. Prior to joining Comsec Distribution, Mr. Bar-Eli served as Head of Channels at Check Point Software Technologies Ltd from 2008 to 2014 and as the Head of Sales for Bynet Data Communication from 2001 to 2008. Mr, Bar-Eli has a B.A. in Business Management from Champlain University and studied Engineering and Management from Tel Aviv University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHT THOUSAND SIX HUNDRED USD BY LFG EQUITIES CORP FOR A ONE DAY HUBC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Sponsored by LFG Equities Corp and Disseminated on Behalf of InMed Pharmaceuticals
Finviz has the Float a TINY 1.2 Mill, highlighting the ability to easily move
InMed’s strong pipeline of treatments, from preclinical stages through Phase 2 trials, showcases the company’s long-term potential and strategic foresight
INM’s Subsidiary Baymedica is Generating Nearly $5Mill in Revenues
InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s disease and ocular and dermatological indications. InMed Pharmaceuticals is not just another biotech firm; it’s a company with the potential to redefine the treatment landscape for Alzheimer’s disease.
INM is an extremely unique hybrid company. They have several pharmaceutical programs supported by a revenue generating business.
INM uses a patented form of cannabinoid molecules. These molecules originally found in Cannabis have long been known for its medicinal properties, including its ability to reduce inflammation, improve symptoms of chronic diseases, and even show potential in cancer treatment.
Several studies have pointed to the neuroprotective effects of cannabinoids which protect brain cells from damage, preserving cognition with is incredibly important for neurodegenerative diseases such as Alzheimer’s. However, the use of cannabinoids in medicine has been limited due to legal and regulatory concerns.
InMed is addressing this challenge by modifying natural cannabinoids to create super effective molecules that could offer even greater therapeutic benefits. These cannabinoid molecules are naturally occurring… however when modified by InMed, their effect could potentially be a game changer for Alzheimer’s disease.
In fact, their treatment, INM-901, is the result of this innovative approach. And what’s incredible is InMed has patented the actual molecules in their treatment, protecting themselves against competitors using identical compounds.
This is the exact type of approach that could get Big Pharma to become a customer rather than a competitor.
Thanks to its unique patented molecules and INM-901 treatment… the potential for success is sky high with this company.
And as the race to tackle Alzheimer’s intensifies, InMed’s innovative approach and strategic positioning make it a standout player in a rapidly growing market.
We know this one can FLY. Just a few weeks ago in early June it ran to 8 bucks on $450 Mill with zero news to speak of. It just got going with some momentum.
INM has the potential to move because it roughly has a market cap OF $3.3M give or take. The valuation might be what really stands out to you. If you can believe it they are sitting below their current cash and have a profitable subsidiary generating roughly $5 million in annual revenue. What INM brings to the table for their investors is exposure to a full pharmaceutical pipeline and commercial subsidiary at essentially no enterprise value.
INM has 3 therapeutic programs in development. The most promising asset may be INM-901, a proprietary oral small molecule targeting Alzheimer’s disease. This represents one of the largest and most underserved markets in medicine.
INM Alzheimer’s preclinical program Highlights:
• Addressing multiple pathologies related to Alzheimer’s Disease
• Reduce neuroinflammation and enhance neuronal functioning in the brain potentially reversing the damage caused by Alzheimer’s disease.
• Importantly, INM-901 may be delivered orally where most drugs in Alzheimer’s need to be administered through IV, which can be very costly and challenging.
• Safely and effectively cross the blood/brain barrier, delivering the drug molecule directly to the brain.
• Successfully crossing the blood/brain barrier is a major challenge to the industry and is important in offering treatment to diseases such as Alzheimer’s.
• Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior and sound awareness in vivo studies– All major hallmarks of this devastating disease.
• Statistically significant reductions in inflammatory and neurodegeneration biomarkers
• Cost-effective, which is increasingly important as the healthcare system looks to balance innovation with accessibility
INM-089: Advancing a Novel Approach in Dry AMD
• INM-089 is InMed’s proprietary small molecule drug candidate targeting dry age-related macular degeneration (AMD)—a condition with no FDA-approved treatment options and affecting over 150 million people globally.
Completed a phase 2 clinical trial in the treatment of Epidermolysis bullosa – Currently seeking strategic partnership for further advancement.
BAYMEDICA
INM Has Built in Insurance with revenue generating & profitable subsidiary BayMedica
While many preclinical-stage biotech companies are entirely reliant on external capital, InMed reduces investor risk through BayMedica, its commercial arm.
This division is cash-flow positive and positioned for potential divestiture, spin-out, or growth partnership—unlocking hidden value.
Undervalued: With a market cap less than its cash position, active revenue stream, disease-modifying Alzheimer’s drug candidate, InMed (NASDAQ: INM) represents a rare value in today’s biotech landscape.
One of the biggest challenges with current Alzheimer’s treatments is while they may slow the rate of cognitive decline, none have been shown to halt or reverse its progression.
Not to mention some of these recently-approved drugs come with major treatment limitations that are incredibly costly and inconvenient for patients.
In fact, most of these treatments only focus on one thing; reducing Amyloid beta plaque.
However, new research suggests this plaque is not the cause of Alzheimer’s and instead is a symptom.[9] That means hundreds of millions of dollars and decades of patient trials haven’t been able to offer a comprehensive cure. In fact, new research suggest the most effective way to treat Alzheimer’s will require a multitude of therapies, not a silver bullet.
This is where InMed’s unique approach comes in!
Not only do their previous preclinical studies show a reduction in amyloid beta plaque but it also shows the potential to be diseases modifying by:
Addressing multiple pathologies related to Alzheimer’s Disease
Reduce neuroinflammation and enhance neuronal functioning in the brain potentially reversing the damage caused by Alzheimer’s disease.
Importantly, INM-901 may be delivered orally where most drugs in Alzheimer’s need to be administered through IV, which can be very costly and challenging.
Safely and effectively cross the blood/brain barrier, delivering the drug molecule directly to the brain.
Successfully crossing the blood/brain barrier is a major challenge to the industry and is important in offering treatment to diseases such as Alzheimer’s.
Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior and sound awareness – All major hallmarks of this devastating disease.
But one of the most exciting developments for INM is the data supporting the growth of neurites. This allows for better cell to cell to communicate within the brain.
In simple terms, this development may indicate the potential to reverse neuronal damage.
An incredible feat that has not been seen in any other treatment available today.
You read that right. This tiny $3M microcap is demonstrating cutting edge developments in Alzheimer’s treatments.
Also the fact that this molecule can be formulated orally is a HUGE advantage. Current treatment options utilizing large molecules often come with serious side effects, such as brain inflammation and bleeding, necessitating periodic brain scans—typically once or twice annually—to monitor these risks. In contrast, small molecule drug candidates present numerous advantages over existing therapies. InMed aims to develop an effective, disease-modifying treatment that is orally administered, ensuring greater accessibility for patients.
Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in
capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well-respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies. He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.
Michael Woudenberg, P.Eng.
Chief Operating Officer
Mr. Woudenberg joined InMed with more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He brings valuable expertise in the development, technology transfer and commercialization of
active pharmaceutical ingredients (APIs) and drug products. Prior to joining InMed in 2018, Mr. Woudenberg held various positions within 3M, Cardiome Pharma, Arbutus Biopharma and most recently as the Managing Director of Phyton Biotech, LLC. His experience includes process and formulation development from lab/pre-clinical products through the various stages of clinical development to validated and successfully approved and inspected commercial APIs and drug products. Additionally, he has extensive experience with regards to regulatory inspections (e.g. FDA, European, Australian, Korean, Japanese, Canadian) and their related chemistry, manufacturing and control requirements from clinical to commercial production of approved products.Mr. Woudenberg received his Bachelor of Science, Chemistry and Bachelor of Engineering Science, Chemical at Western University of London, Ontario, Canada.
Netta Jagpal, CPA
Chief Financial Officer
Ms. Jagpal joins InMed with over 20 years of experience in financial leadership roles, primarily in the biotech industry. Prior to InMed, Ms. Jagpal served as Vice President, Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS) where she led a finance team through the initial public offering process.
Prior to D-Wave, Netta spent 11 years at Zymeworks Inc. (NYSE: ZYME), a leading Vancouver based clinical stage biopharmaceutical company, in various financial roles including Senior Director, Finance & Corporate Controller. Netta has also previously held roles at Angiotech Pharmaceuticals, Inc. (NASDAQ: ANP) and Ernst & Young. Netta is a Chartered Professional Accountant with the Institute of Chartered Accountants of British Columbia and holds a Bachelor of Business Administration degree in Accounting and Organization Behaviour from Simon Fraser University.
Eric C. Hsu, PhD
Senior Vice President, Pre-Clinical Research & Development
Dr. Hsu joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. Prior to joining InMed, he held various positions within enGene Inc., including V.P. of Research and V.P. of Scientific Affairs and Operations.
Dr. Hsu’s experience includes a wide array of activities, including benchtop research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships. He is also responsible for expanding product pipelines, and managing R&D budgets and timelines. Dr. Hsu is considered to be an expert in gene transfer and gene expression using vector systems.Dr. Hsu received his Doctorate from the Department of Medical Biophysics at the University of Toronto and his Bachelor’s degree from McGill University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND THREE HUNDRED SEVENTY FIVE USD BY LFG EQUITIES CORP FOR A ONE DAY INM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
IQST Runs a Diversified Business with Divisions Focused on Telecommunications, Fintech, Electric Vehicles, Artificial Intelligence and More
IQST reported $77.8 million in preliminary net revenue for the first four months of 2025, representing 12% growth over the same period in 2024, reconfirming full-year revenue guidance of $340 million
IQST ran the Gamut From Pink Sheets to QB, then OTCQX, and now NASDAQ Just Last Month! —without a capital raise or any shareholder dilution
Company Just Sparked Rapid Global Fintech Expansion with GlobeTopper Acquisition — Fast-Tracking $1 Billion Growth Plan
Hello everyone,
This is going to be a busy week for us. We decided to kick it off with a past winner. We know the fireworks aren’t for a few weeks but this one was a half stick of dynamite the last time this ticker was on our screen. It wasn’t long ago. This company uplisted to the Nasdaq last month. Not an easy journey. When we brought it to your attention last time, this hidden gem proceeded to go crazy over the next two sessions. It kicked off a short squeeze that absolutely nobody was anticipating.
It opened that session at 8.92 And then the next session it hit 14.70 on record interest. It was a huge 65% winner for us. It started to hit scanners because of the massive single day movement and a short squeeze kicked off.
We feel as though IQST is back in a situation where a short squeeze has the potential to take place.
Since we last looked at this one, the dilution has been extremely minimal, Not even worth mentioning so we know the flow is tight and the potential for it to perform as it had in the past is still in play.
Take a look at the chart here. The setup is very similar. Look at that. The two green candle sticks were the days we sent out our IQST profile.
Since that triumphant run, this one has closed red 8 of the last 9 and 10 of the last 12. The opportunity for a bounce and a squeeze right now is huge. We are going to have to watch and see how things are shaping up premarket.
IQST has dropped a few press releases since we last looked at it with one of them, highlighting massive revenue of $77 Mill for the first 4 months of the year.
The growth alone is jaw dropping as the company claims to be on track to 1 Billion in Revenues by 2027. It just uplisted to the Nasdaq without any raise or dilution.The CEO says the company came to the Nasdaq with 20,000 shareholders.
The float has to be tiny. The company just completed a 1 for 80 reverse weeks back, drastically reducing the outstanding.
This is a company that is not to be overlooked at these levels. IQST is a multinational technology company offering cutting-edge solutions in Fintech, Blockchain, Artificial Intelligence (AI), and Cybersecurity. Telecom, High-Tech Telecom Services (eSIM, roaming, cloud), with over 600 global business relationships.They deliver high-value, high-margin services to its extensive global customer base.r
In 2024, IQSTEL reported $283 million in revenue, yet their market cap remained at only about 10% of that figure. They also achieved 96% year-over-year revenue growth but valuation has not kept pace with performance, leaving plenty of room for growth for IQST.
MAIN CUSTOMERS
IQST – IQSTEL Sparks Rapid Global Fintech Expansion with GlobeTopper Acquisition — Fast-Tracking $1 Billion Growth Plan
NEW YORK, May 29, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST), a rapidly expanding multinational leader in telecommunications and emerging technologies, proudly announces the execution of a definitive agreement to acquire 51% of GlobeTopper — a dynamic fintech innovator with operations across America, Europe, and Africa. The transaction becomes effective July 1, 2025, marking a transformative milestone in IQSTEL’s journey toward becoming a $1 billion revenue corporation.
This milestone follows the signing of a Memorandum of Understanding (MOU) on March 21, 2025, and reinforces IQSTEL’s strategic vision to scale its high-tech fintech footprint globally.
GlobeTopper’s Vision and Forecasts
GlobeTopper’s strong market positioning is evident in its current standalone performance — planning to generate over $65 million in profitable revenue in 2025 alone. Its financial outlook for the next three years reflects steady growth and operational momentum.
Strategic Vision: A Masterpiece Commercial Move
IQSTEL’s decision to acquire GlobeTopper is rooted in a bold and deliberate strategic vision.
“We didn’t just acquire a company—we partnered with a growth engine,” said Leandro Iglesias, CEO of IQSTEL.
“Our goal is to take GlobeTopper’s innovative fintech products and services and scale them globally through IQSTEL’s powerful commercial platform — which already reaches over 600 of the largest telecom operators around the world.”
In parallel, GlobeTopper’s existing client base — including prominent multinational brands — opens the door for IQSTEL to expand its reach into new sectors, allowing deeper penetration into the enterprise and global brand markets.
“We believe the potential for growth is massive,” Iglesias continued. “This isn’t just an acquisition — it’s a masterpiece commercial move that brings together two agile organizations and sets the stage for something extraordinary.”
Together, IQSTEL and GlobeTopper will lead the next wave of convergence between fintech and telecommunications in high-value markets across Africa, Europe, and the Americas.
Strategic Synergy and Ongoing Leadership
As part of the transaction, Craig Span will continue in his role as CEO of GlobeTopper, ensuring leadership continuity and seamless integration into IQSTEL’s Fintech Division.
“This partnership with IQSTEL marks a new era for GlobeTopper,” said Craig Span, CEO of GlobeTopper.
“We’re incredibly excited to join forces with a Nasdaq-listed company that shares our vision, values, and ambition. With IQSTEL’s support, we’re ready to fast-track our growth and become a major player in the global fintech space.”
GlobeTopper will collaborate with GlobalMoneyOne.com, co-developing a 3-year business plan to position itself as a top-tier player in the global fintech ecosystem.
Accelerating Toward $1 Billion
“We’ve helped subsidiaries scale before, and we’re doing it again with GlobeTopper,” said Iglesias.
“This deal puts us firmly on track to reach a $400 million revenue run rate and achieve our targeted 80% telecom / 20% tech revenue mix by the end of this year.”
This acquisition strengthens IQSTEL’s position as a high-margin, tech-focused growth platform, advancing its $1 billion revenue goal by 2027.
Transaction Highlights
The transaction is valued at up to $700,000, structured to align performance with shareholder value:
$200,000 in staged cash payments
$500,000 in restricted IQSTEL common stock, issued at a 20% discount to the 5-day VWAP prior to closing
Performance-based Earn-Outs:
50% of EBITDA growth in Year 1 (paid in IQSTEL shares)
50% of EBITDA growth in Year 2 (paid in IQSTEL shares)
Earn-out shares priced at a 20% discount to the higher of the 5-day VWAP.
Additionally, IQSTEL plans to invest up to $1.2 million over the next 2 years to accelerate GlobeTopper’s growth and product roadmap. This investment is contingent upon GlobeTopper meeting specific quarterly financial targets, ensuring performance-driven alignment throughout the integration.
What’s Next
With GlobeTopper now part of the IQSTEL family, the company is moving faster and stronger toward its vision. IQSTEL remains laser-focused on scaling high-tech divisions, expanding its global footprint, and maximizing shareholder value.
“We’re building something big” added Iglesias — and the entire IQSTEL ecosystem is gaining powerful momentum”
About GlobeTopper
GlobeTopper is a leader Fintech company specializing in advanced B2B Top-Up solutions, enabling seamless cross-border financial transactions to something more along the lines of ‘global Fintech company specializing in the provision of B2B digital prepaid products with a unique focus on gift card programs and services. With a solid track record and a scalable, profitable business model, GlobeTopper is poised for exponential growth under IQSTEL’s leadership.
The details of this acquisition will be disclosed in an upcoming Form 8-K filing.
— IQSTEL Inc. (NASDAQ: IQST) (@IQstel) May 23, 2025
IQST – IQSTEL Reports Preliminary $77.8 Million in Revenue Through April 2025 — Confirms Full-Year Guidance and Fast-Track to $400M Run Rate
PUBLISHED
JUN 5, 2025 8:22AM EDT
NEW YORK, June 5, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST), a leading multinational telecommunications and technology company, is pleased to announce that its preliminary net revenue for the first four months of 2025 (January through April) totaled approximately $77.8 million, continuing the company’s strong growth momentum and reinforcing its confidence in full-year revenue guidance.
This preliminary figure reflects a 12% increase compared to the same period in 2024, highlighting the strength and consistency of IQSTEL’s organic growth across its core telecom operations.
“We’re pleased with how 2025 has begun,” said Leandro Iglesias, CEO of IQSTEL. “Historically, the second half of the year has delivered even stronger performance, and we fully expect that trend to continue. With these results, we remain on track to reach our full-year revenue forecast of $340 million.”
Accelerating with Fintech Expansion
IQSTEL’s recent acquisition of GlobeTopper, a profitable fintech company with operations across the Americas, Europe, and Africa, is expected to further accelerate growth. The transaction positions IQSTEL to reach a $400 million annualized revenue run rate with a projected 80% telecom / 20% fintech-tech revenue mix by year-end.
Profitability Trends Upward
IQSTEL´s operating business anticipates generating over $3 million in adjusted EBITDA in 2025, with positive net income in the seven-digit range, driven by operational efficiencies, scalability, and its increasing focus on high-margin services.
Vision 2027: $1 Billion Revenue
IQSTEL continues to execute its strategic roadmap to become a $1 billion revenue company by 2027, combining organic growth, targeted acquisitions, and expansion in key technology sectors, including cybersecurity, AI, managed services, and fintech.
“We’ve already achieved critical mass, so every dollar of new revenue has an outsized impact on our bottom line,” added Iglesias. “With GlobeTopper, our telecom platform, and a growing ecosystem of innovation, we are building something big — and we’re just getting started.”
NASDAQ Uplisting: A New Chapter of Acceleration
IQSTEL’s recent uplisting to NASDAQ has already begun to catalyze momentum. The increased visibility and credibility among institutional investors are expected to unlock new strategic opportunities and financial partnerships.
“Being on NASDAQ is a game changer,” concluded Iglesias. “It’s a sign to the market that we’re operating on a higher level. 2025 is shaping up to be a remarkable year — and it’s just the beginning.”
IQSTEL and Cycurion (CYCU) Unveil Plans for AI-Powered Next-Generation Cybersecurity Platform, Targeting the Global Telecom Industry
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) — Cycurion Inc. (NASDAQ: CYCU), a trusted leader in IT cybersecurity solutions and AI, and IQSTEL Inc. (NASDAQ: IQST), a leading provider of high-tech telecommunications and technology solutions, are pleased to announce the advancement of their strategic partnership, originally signed a few months ago.
Since entering into the agreement, both companies have worked closely to define and design customized cybersecurity solutions for the evolving needs of the global telecom industry. The collaboration is now entering an execution phase, focused on product rollout and market deployment.
Six Pillars of Collaboration
1. Cybersecurity for Telecom Carrier Infrastructure
IQSTEL and Cycurion are developing advanced cybersecurity solutions to protect critical telecom carrier operations, including:
Destination rates
Routing engine rules
Billing and accounting systems
CRM and ERP platforms
Sensitive customer and vendor financial information
These protections are designed to fortify telecom networks against breaches and operational risks.
2. White-Label Cybersecurity Services for Telecom Operators
The companies are launching “Cyber Shield,” a white-label cybersecurity platform that major telecom carriers can offer to their own customers, including:
Large enterprises
Medium-sized businesses
Individual consumers
This solution enables telecom operators to add high-margin cybersecurity services to their portfolio—strengthening customer retention and unlocking new revenue streams.
3. AI-Driven Operational Optimization for Cycurion
Cycurion is exploring integration of IQSTEL Intelligence, a proprietary AI platform, to:
Optimize internal operations
Reduce costs
Accelerate execution of high-value contracts currently under negotiation
IQSTEL and Cycurion are collaborating to develop an AI-Powered Next-Generation Cybersecurity Platform, with the initiative led by IQSTEL’s Intelligence Division—the company’s dedicated unit for advanced AI research and development.
This new platform is designed to:
Increase predictive protection, enabling the identification and neutralization of threats before they materialize
Enhance adaptive response, allowing intelligent, real-time countermeasures that evolve with new attack patterns
By combining Cycurion’s deep cybersecurity expertise with IQSTEL’s proprietary AI technologies, the companies aim to deliver a cutting-edge, proactive defense system built specifically for telecom operators and large-scale digital ecosystems. This initiative positions IQSTEL and Cycurion as global leaders in AI-enhanced telecom cybersecurity.
5. Time-to-Market in H2 2025
The two companies are actively planning a commercial launch in the second half of 2025. Joint teams are aligning on product development, packaging, and go-to-market strategies to ensure a coordinated, global rollout.
6. Cybersecurity Market Size and Global Opportunity
According to industry forecasts, the global cybersecurity market is expected to surpass $500 billion by 2030, fueled by rapid digital transformation, cloud adoption, and escalating cyber threats.
The telecom sector, responsible for massive data flows and sensitive information, urgently requires robust digital defense. IQSTEL and Cycurion are uniquely positioned to serve this demand, combining AI and cybersecurity into a scalable, telecom-specific solution.
With a presence in more than 20 countries across 4 continents and established commercial relationships with over 600 telecom operators, IQSTEL provides an ideal platform to deliver world-class cybersecurity solutions at global scale.
Leandro Iglesias, CEO of IQSTEL, commented:“We are excited to advance our partnership with Cycurion. After months of collaborative development, we are confident that our joint cybersecurity and AI services will bring significant value to telecom carriers and their global customers.”
Kevin Kelly, CEO of Cycurion, added:“Partnering with IQSTEL has enabled us to build intelligent, scalable solutions tailored for telecom. Their AI expertise complements our cybersecurity strategy, setting us up for global impact.”
About Cycurion Inc.
Cycurion Inc. (NASDAQ: CYCU) is a cybersecurity company specializing in data protection, threat management, and compliance solutions for corporate, government, and telecom clients. Cycurion’s mission is to empower organizations with intelligent, adaptive security that evolves with today’s digital landscape.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND EIGHT HUNDRED USD BY CORPORATE ADS LLC FOR A ONE DAY IQST AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Litecoin Foundation Partners With Digital Asset Manager Metalpha to Develop Hedging Products for LTC Miners
Crypto Mining Giant Bitmain Owns Over 38% of MATH Through Various Entities Bitmain is a Multi-Billion Dollar Company
Antalpha Owns 24% of MATH. They Just IPO’d 3 Weeks ago and Have a $290M Market Cap
Metalpha Partners with DogeOS to Expand Crypto Innovation and Promote Dogecoin’s Vision
_________________________
Hello Everyone,
We have an urgent situation that we wanted to bring to your attention right away.
You definitely remember MATH. It has doubled since we first put the ticker on your plate.
It has been an absolute monster and all signs are pointing to this one being far from over.
We profiled it back in February and it closed at 1.89 on the session. Then we looked at it just a couple of weeks ago at 3.30 or so.
Just last week MATH exploded through the 52 week high and hit 4.17. That is 100%+ move since the first time we brought you MATH just a few short months ago. It made a 20%+ move the second time.
Right now it has pulled back to 3 Bucks on EXTREMELY light interest. Couple that with the recent increase in shorts and what we have is a very unique situation to pay attention to on Friday.
We expect that MATH could retest the 52 week highs on the next run if and when that takes place. There is no denying how MATH chewed through resistance
Let’s not forget who owns 38% of the company. Bitmain is not a household name but they do a half billion in revenues. They are massive in the crypto world. 38% is not a small position.
If you look at Interactive Brokers you will see that over a million shares are being borrowed at VERY high rates.
The structure on MATH appears to be tight and this thing just chewed through resistance before the short sellers started getting aggressive.
You are going to want to watch MATH in the premarket and at the open. I do not have a crystal ball and have no idea what will happen tomorrow but I will say that I would not be surprised if we see MATH north of 4 bucks tomorrow. Only time will tell and we will have to check back in to see.
MATH has been on the move since mid April and just today broke the 52 week high last week before the pullback.
Notice on the chart from the middle of February when after we profiled it and it set a new 52 week high
One of Metalpha’s biggest advantages is backing from industry giants Bitmain and Antalpha Technologies (NASDAQ: ANTA). These partnerships provide Metalpha with a unique edge in the market that few competitors can match.Bitmain, the world’s leading manufacturer of Bitcoin mining hardware, has a 38.6% stake in Metalpha. This key strategic partnership allows Metalpha to structure derivative products that directly benefit from Bitmain’s dominance in the BTC mining supply chain. Metalpha gets access to liquidity and business opportunities unavailable to a standalone crypto financial services firm.Another major MATH shareholder, Antalpha Technologies, also plays a pivotal role in Metalpha operations by bringing in institutional expertise and capital efficiency. Antalpha has a history of working with crypto mining firms and digital asset holders to optimize allocations, making it a valuable partner in expanding Metalpha’s wealth management solutions. As global crypto markets continue to evolve, strategic backing from heavyweight firms like these means that Metalpha can pivot and scale rapidly, unlocking long-term value for investors.
Metalpha Announces Successful Conclusion of Next Generation Fund with Exceptional Performance
HONG KONG, June 12, 2025 /PRNewswire/ — Metalpha Technology Holding Limited (Nasdaq: MATH) (“Metalpha” or the “Company”), a leading digital asset-focused wealth management company, today announced the successful completion of the LSQ Investment Fund SPC – Next Generation Fund I SP (the “Fund”), which delivered exceptional results over its two-year investment period.
The Fund, managed by Metalpha’s SFC Type 9 licensed subsidiary LSQ Capital Limited, commenced trading activities in late March 2023. From late March 2023 to March 2025, the Fund achieved a net asset value (NAV) performance of 375.5%, outperforming BTC by 67.3%, as tracked under by Bloomberg (ticker: LSQNEXI).
“The performance of Fund exemplifies our commitment to delivering strong investment outcomes through deep market insight, prudent risk management, and close collaboration across our partners,” said Mr. Adrian Wang, CEO of Metalpha. “We’re proud to have created significant value for our investors and will continue to pursue innovative and compliant solutions in the digital asset space.”
Following the conclusion of the Fund’s lifecycle, Metalpha is glad to transfer all of its 40% equity interest in NextGen Digital Venture Limited to Mr. Jason Huang, a key contributor to the Fund’s success. The Company believes this transition will further strengthen the strategic cooperation between the Company and NextGen and ensure continued excellence in fund management and innovation. The proposed transaction and the terms of which have been reviewed and approved by the board of directors of the Company.
“We extend our sincere congratulations to Jason and wish him every success in leading NextGen Digital Venture Limited toward greater achievements in future,” added Mr. Wang.
“I am deeply grateful to Adrian and the Metalpha team for their partnership in achieving 375.5% NAV performance with 67.3% outperformance against Bitcoin over two years,” said Mr. Jason Huang, Founder of NextGen Digital Venture Limited. “NextGen Digital Venture Limited has launched Fund II to continue our focus on crypto-related equity investments as we believe digital assets represent the new frontier of finance. With regulatory frameworks and technological innovation just beginning to unfold, we remain committed to capturing transformative opportunities at the intersection of crypto and traditional finance.”
A Bitcoin Play That Doesn’t Need BTC
Metalpha operates as a digital asset wealth management firm specializing in exotic derivatives. This structure allows Metalpha to thrive in both bull and bear markets, making it a unique and compelling investment opportunity in the crypto space.
One of the most compelling aspects of Metalpha is that it is not directly tied to Bitcoin’s price movements in the same way as traditional mining or holding companies. Rather than simply accumulating Bitcoin on its balance sheet, Metalpha profits from offering structured derivative products to institutional investors. This means that regardless of Bitcoin’s direction, the firm can generate strong revenue through its financial products.Additionally, Metalpha’s strategic partnership with Bitmain, the world’s largest manufacturer of Bitcoin mining hardware, allows it to mine Bitcoin in-house—in essence, purchasing Bitcoin at a 20% discount.
This is a massive advantage, as it allows the company to source BTC at lower costs while enhancing its profitability. Derivatives and structured products are essential components of mature financial markets, and Metalpha’s expertise in this area gives it a significant competitive edge. Unlike miners, who are forced to liquidate Bitcoin to cover operational expenses, Metalpha’s business model enables it to generate sustainable and recurring revenue from institutional clients seeking exposure to digital assets without the direct volatility risk.Their clients include institutions, exchanges, mining companies, investment funds, and family offices. For many of the mining companies they offer a product that couples financing of the mining rigs from partner Bitmain with offering returns from the digital assets. This is a win-win for miners and creates a sticky customer base for their strategic partner Bitmain.
Revenues for 2024 came in at $16.8 million and they recorded a net loss of $.11 per share. The company also had a shareholder equity of $16.8 million. They had a net profit of $1.3 million for the year but it was offset by a large warrant expense which resulted in a small loss for the year. The balance sheet contained $126.5 million in crypto assets. As of March 2024 they had transaction volume of $1.6 billion in BTC. Given their trajectory this number could be closer to $3 – 4 billion based on the appreciation of BTC and their growth rate. There are 39.0 million shares outstanding and 20.6 million are held by partners and 5.5 million are held by insiders leaving, almost 13.0 million shares left in the float.
Key shareholders in MATH include Bitmain which is the primary hardware supplier of Bitcoin mining rigs and Antalpha which provides the technical support for the hardware and has a strategic partnership with them. The insiders and strategic partners hold just over 50% of MATH.
Other notable partners include Bloomberg, CoinDesk, Tether, Bloomberg, Morningstar, and Interactive Brokers Group
Regulatory Landscape and Compliance Strength
One of the biggest challenges facing the crypto industry today is regulatory uncertainty. However, Metalpha has positioned itself as a compliant, institutional-grade platform by proactively securing the necessary regulatory approvals and operating within clearly defined legal frameworks.Metalpha’s wholly owned subsidiary, LSQ Capital Limited, is licensed by the Hong Kong Securities and Futures Commission (SFC) with Type 4 (advising on securities) and Type 9 (asset management) licenses. This regulatory approval provides institutional investors with the confidence that Metalpha adheres to strict compliance standards, ensuring transparency and risk management.With increasing global scrutiny over crypto firms, Metalpha’s compliance-first approach gives it a significant advantage over competitors operating in regulatory gray areas. Additionally, as jurisdictions like Hong Kong, the UAE, and the EU continue refining crypto regulations, Metalpha is well-positioned to capitalize on institutional inflows that require fully compliant investment vehicles.
MMetalpha’s key competitive advantages include:●Institutional Focus — Unlike retail-focused platforms, Metalpha designs investment solutions specifically for hedge funds, family offices, and high-net-worth individuals looking for custom derivative products.●Strong Strategic Partnerships — Backing from industry leaders like Bitmain and partnerships with firms like Zodia Markets give Metalpha a unique edge in market access and liquidity.●Risk Management Expertise — Traditional crypto investment vehicles are prone to extreme volatility, but Metalpha’s derivative-based strategies allow clients to mitigate risk while still gaining exposure to digital assets.As the market matures, institutions will demand more sophisticated crypto investment tools. Metalpha is ahead of the curve, positioning itself as a premier provider of customized digital asset solutions for the next wave of institutional adoption.
Metalpha’s key competitive advantages include:
●Institutional Focus — Unlike retail-focused platforms, Metalpha designs investment solutions specifically for hedge funds, family offices, and high-net-worth individuals looking for custom derivative products.
●Strong Strategic Partnerships — Backing from industry leaders like Bitmain and partnerships with firms like Zodia Markets give Metalpha a unique edge in market access and liquidity.
●Risk Management Expertise — Traditional crypto investment vehicles are prone to extreme volatility, but Metalpha’s derivative-based strategies allow clients to mitigate risk while still gaining exposure to digital assets.As the market matures, institutions will demand more sophisticated crypto investment tools. Metalpha is ahead of the curve, positioning itself as a premier provider of customized digital asset solutions for the next wave of institutional adoption.
Metalpha Partners with DogeOS to Expand Crypto Innovation and Promote Dogecoin’s Vision
Strategic Alliance Combines MyDoge’s Retail Legacy with Institutional Expertise to Drive DOGE Innovation
HONG KONG, June 5, 2025 /PRNewswire/ — Metalpha Technology Holding Limited (Nasdaq: MATH) (the “Company” or “Metalpha”), through its subsidiaries, is dedicated to providing digital asset-focused wealth management services with a full- service, institutional-grade platform. Today, the Company announced a partnership with DogeOS—the application layer founded by the MyDoge team—to accelerate Dogecoin’s (DOGE) evolution as a market-leading cryptocurrency. This collaboration unites Metalpha’s institutional support for proof-of-work (PoW) ecosystems with DogeOS’s vision to transform DOGE into a versatile blockchain platform for gaming, DeFi, and AI.
Why Dogecoin? A Community-Driven Crypto Powerhouse
For Dogecoin, the arrival of Metalpha’s infrastructure-oriented investment marks a strategic inflection point. With over 4 million daily transactions and a market capitalization that consistently ranks among the top 10 cryptocurrencies, DOGE has emerged as the world’s most valuable memecoin, bridging internet culture with blockchain utility. However, Dogecoin has operated primarily on centralized exchanges, limiting its potential for decentralized finance applications and productive use cases.
Through this partnership, Metalpha will bring institutional liquidity that may enter productive use cases within the DogeOS ecosystem. This liquidity could enable native DOGE yield and DeFi opportunities, providing Dogecoin holders with meaningful utility beyond trading for the first time.
“By partnering with DogeOS, we’re extending our decade-long support for PoW innovation—from Bitcoin mining indices to Litecoin sustainability programs—to help DOGE unlock enterprise-grade applications.” said Metalpha CEO Adrian Wang.
DogeOS: The App Layer for Dogecoin, Built by MyDoge Team
Founded by the creators of MyDoge (the leading Dogecoin wallet with over 500,000 users), DogeOS is engineered to amplify DOGE’s cultural identity while attracting mainstream developers. Backed by $6.9 million in funding led by Polychain Capital, DogeOS provides tools to build consumer apps ranging from AI integrations to gaming platforms.
“Our mission is to make Dogecoin the most developer-friendly PoW blockchain,” said Jordan Jefferson, CEO and Founder of DogeOS. “With Metalpha’s expertise in scaling mining ecosystems, we’ll bridge DOGE’s retail passion with institutional-grade infrastructure.”
Metalpha’sCommitmenttoPoWEcosystems
This partnership extends Metalpha’s leadership in supporting proof-of-work networks:
Bitcoin Mining Leadership: Developed the Bitcoin Miner Index and partnered with Antalpha to democratize institutional exposure.
Litecoin Sustainability: Co-developed hedging tools and carbon-neutral mining initiatives with the Litecoin Foundation.
Ecosystem Expansion: Through the Hong Kong Sustaintech Foundation, Metalpha sponsored research on PoW energy efficiency at Hong Kong Polytechnic University.
About DogeOS
DogeOS is the App Layer for Dogecoin, where community, culture, and liquidity come together to power the next generation of consumer apps. Founded by the team behind the MyDoge, the #1 Dogecoin wallet, DogeOS champions Dogecoin as the people’s currency by empowering developers to build experiences in gaming, DeFi, AI, and more – all backed by the world’s most iconic crypto brand.
To learn more about DogeOS and its mission to transform Dogecoin from a meme chain to a thriving app ecosystem, visit dogeos.com and follow DogeOS on X at x.com/DogeOS.
Metalpha Announces Joint Venture with Abu Dhabi based Gewan Holding and subsidiary of Standard Chartered Zodia Markets to Expand into the Middle East Digital Asset Market
HONG KONG, Feb. 10, 2025 /PRNewswire/ — Metalpha Technology Holding Limited(Nasdaq: MATH) is pleased to announce that its wholly owned subsidiary, Metalpha Limited, has partnered with Gewan Holding and Zodia Markets to establish ZMG7 LLC, a joint venture aimed at driving the growth of the digital asset market in the Middle East. This milestone partnership marks a significant step in the company’s global expansion strategy and strengthens the UAE’s position as a key hub for digital asset management.
Abu Dhabi-based Gewan Holding, renowned for its diverse portfolio of strategic investments across various industry sectors, has long been a driver of innovation in the UAEcapital’s financial sector, and beyond.
Zodia Markets is a subsidiary of Standard Chartered, a UK bank with a presence largely in emerging markets, such as Asia, Africa and the Middle East. Standard Chartered launched Zodia Markets in 2021 alongside OSL, in a move that highlighted the Bank’s desire to be leaders in the development of global digital-asset infrastructure.
Adrian Wang, CEO of Metalpha Technology Holding Limited, commented: “I’m very excited for our partnership and shared vision of advancing digital assets in the Middle East. Aiming to play a pivotal role to drive mass adoption of digital assets in the region, we look forward to expanding our presence in this dynamic market.”
The formation of ZMG7 LLC comes at a time when the UAE is actively embracing fintech innovation and digital asset regulatory frameworks. As part of this joint venture, Metalpha will leverage its expertise in derivatives innovation, market structure optimization, and risk management to support ZMG7 LLC in building a fully compliant and globally competitive digital asset trading and wealth management platform.
Metalpha Reports Half-Year FY2025 Financial Results with Revenues up Nearly Four-fold, and Announces a $5 Million Share Repurchase Program
HONG KONG, Feb. 13, 2025 /PRNewswire/ — Metalpha Technology Holding Limited (Nasdaq: MATH) (the “Company” or “Metalpha”), a global leader in digital asset wealth management, is pleased to announce its unaudited financial results for the six months ended September 30, 2024, with revenue up by an impressive 388% compared to the same period in FY2024. The Company also announced today that its Board of Directors has approved a share repurchase program of up to $5 million, reflecting confidence in the Company’s future growth. Since the announcement of the Company’s joint venture with Antalpha Technologies Limited on November 8th, 2021, Metalpha has grown to become a leader in digital asset wealth management, with its robust financial performance demonstrating substantial growth amid increasing adoption of cryptocurrency.
FY2025 Interim Results Highlights
For the six months ended September 30, 2024, Metalpha achieved total revenue of $19,720,654, nearly fourfold compared to $5,085,150 for the same period in FY2024. Net income reached $6,044,921, a remarkable turnaround from a net loss of $3,856,955 in the prior-year period. The growth was driven by the pursuit of delivering high-quality products and services to clients. The following table presents the Company’s total revenue and net income (loss) for each of the six-month period ended September 30, 2024, March 31, 2024, September 30, 2023 and March 31, 2023:
For the Six Months Ended
September 30, 2024
March 31, 2024
September 30, 2023
March 31, 2023
Total Revenue
$19,720,654
$11,678,395
$5,085,150
$1,753,186
Net Income
(Loss)
$6,044,921
$177,546
($3,856,955)
($7,033,059)
For further information regarding the Company’s unaudited financial results for the first six months of fiscal year 2025, please refer to the unaudited consolidated financial statements of the Company as of September 30, 2024 and for the six months ended September 30, 2024, furnished to the U.S. Securities and Exchange Commission on Form 6-K and available at www.sec.gov.
$5 Million Share Repurchase Program
Metalpha’s Board of Directors has approved a share repurchase program of up to $5 million over the next 36 months. The Company’s repurchases may be made from time to time through open market purchases, privately negotiated transactions, or other legally permissible methods, depending on market conditions and the Company’s capital requirements.
This share repurchase program reflects Metalpha’s confidence in its long-term strategic direction and commitment to deliver value to its shareholders. Through disciplined capital allocation, Metalpha aims to enhance per-share value and provide long-term returns for its investors.
Adrian Wang, chairman and CEO of Metalpha, expressed optimism about the Company’s future:
“The robust interim results, coupled with our growing partnerships and expanded financial offerings, showcase our commitment to meet the customer demand. Behind the attractive financial numbers, we made significant investments in areas that are less apparent but even more critical to our success. Best talents, state-of-the-art technology infrastructure, and extremely comprehensive internal control systems are all essential for long-term scalability and sustainability. These efforts demonstrate our dedication to excellence. Looking ahead, we remain focused on advancing technology, enhancing customer experiences, and innovating best digital asset derivative products.”
Metalpha Technology Holding Limited Lists on Frankfurt Stock Exchange
HONG KONG, May 20, 2025 /PRNewswire/ — Metalpha Technology Holding Limited (Nasdaq: MATH) (“Metalpha” or the “Company”), a leading digital asset wealth management company, today announced that its shares have been made available for trading on the Frankfurt Stock Exchange under the ticker symbol FSE: D92. The Company will continue to maintain its primary listing on the Nasdaq Stock Market.
“We welcome the additional listing on the Frankfurt Stock Exchange, which we believe will increase visibility and accessibility for investors in Europe,” said Mr. Adrian Wang, Chief Executive Officer of Metalpha. “As global interest in digital asset investment continues to grow, we remain committed to serving our clients and shareholders with robust, compliant, and innovative financial solutions.”
The Frankfurt Stock Exchange (FSE) is one of the largest securities trading venues globally and the largest exchange in Germany. The inclusion of Metalpha shares on the FSE is expected to facilitate investor access across European and international markets.
Litecoin Foundation Partners With Digital Asset Manager Metalpha to Develop Hedging Products for LTC Miners
The partnership will jointly develop the Litecoin ecosystem to hedge risk and lower carbon emissions.
Metalpha Technology Holding Ltd (MATH), a wealth management company for cryptocurrencies, said on Friday it will work with Litecoin Foundation to develop sustainable mining solutions for the Litecoin ecosystem.
The Litecoin foundation is a nonprofit that maintains and develops products for the namesake blockchain.
The partnership’s specific areas of research will include developing derivative products, facilitating renewable energy use, increasing energy efficiency and lowering carbon emissions from mining on the Litecoin Network.
Metalpha will develop financial derivative products for LTC tokens, it also aims to support crypto miners with hedging products against market risk and to lower the environmental impact of crypto mining.
Hedging is a risk management strategy employed to offset losses in investments by taking an opposite position in a related asset.
Metalpha and Litecoin Foundation added they will work with universities and research institutions to further sustainable blockchain innovation, support public education around the Litecoin network, and improve network awareness, adoption and scalability.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE NOT BEEN COMPENSATED BY GLOBAL INDUSTRIAL SOLUTIONS LLC FOR A ONE DAY MATH AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
SAFX is the first publicly traded pure-play SAF producer in the US – Market and Regulatory Tailwinds Are STRONG!
Hello Everyone,
We want to direct your attention to a completely new opportunity. We have never profiled this company before and for good reason……. It just started trading on the Nasdaq last week. This is another ground floor opportunity that deserves a closer look.
This one is a high risk / high reward bounce play. Once this finds bottom it could see a massive bounce.
Pull up SAFX and put it on your screen.
XCF Global (NASDAQ:SAFX) is a US-based clean energy company focused on producing synthetic aviation fuel (SAF) and other renewable fuels to decarbonize the transportation sector.
The company’s core strategy focuses on acquiring dormant biodiesel facilities across the US and converting them to produce SAF. Using non-food feedstocks such as waste oils, fats, and agricultural residues. SAFX produces synthetic aviation fuel which has lifecycle carbon emissions reductions of up to 80% versus traditional jet fuel.
And the timing couldn’t be better.
The latest Aegis report shows D4 RIN prices holding above $1, signaling surging demand for renewable fuels across California, Oregon, and other compliance-driven markets. Meanwhile, the EPA just proposed record-high biofuel blending targets through 2027—a move widely seen as a historic endorsement of low-carbon fuels at the federal level.
“This is the highest ever Renewable Volume Obligation and it sends a strong signal to the US biofuels industry that President Trump has their backs and gives them the incentive to invest in American products for American consumers and to export around the world,” – US Secretary of Agriculture Brooke Rollins
Together, these dual tailwinds—strong market pricing and aggressive federal policy—are accelerating the economics for SAF producers like SAFX.
First SAF deliveries from SAFX rolled in March, giving the company early cash flow. From there, the facility began ramp-up processes to improve output. During ramp-up, the facility is temporarily producing renewable diesel at nameplate capacity (~3,000 barrels per day!) and expects to bring SAF production back online in Q3.They are one of only seven active SAF facilities in North America and among roughly just 40 globally!
SAFX has actual production, real revenue, and proven technology and now they are publicly traded.
Beyond New Rise Reno, XCF Global has acquired three additional sites including a second facility in Nevada expected to come online in 2027, and two more in Wilson, North Carolina and Fort Myers, Florida which are scheduled for conversion to SAF production by 2028. The addition of these facilities is expected to bring XCF Global’s total capacity to approximately ~160 million gallons annually by 2028!
Backing it is a 15-year feedstock and offtake agreement with Phillips 66, which supplies 100% of the non-food feedstock and acts as the priority buyer for all output from the New Rise Reno facility. This long-term contract provides both cash flow stability and operational flexibility.
SAF is not some hokey theory. A couple of household names have their hands in the sector.
● Richard Branson’s Virgin Atlantic operated Flight100, the world’s first transatlantic flight powered entirely by SAF, demonstrating the fuel’s viability.
● Bill Gates invested in SAF indirectly through Breakthrough Energy Ventures, which backed ZeroAvia, a company developing hydrogen-electric engines for aircraft.
● Formula One World Champion Damon Hill has invested in Zero Petroleum, a UK-based company producing synthetic fuels, including SAF.
Major airlines are also fully committed:
● “Sustainable aviation fuel is the most promising lever known today to accelerate progress toward a net-zero future.” – Delta Air Lines
● “The clearest near-term way to decarbonize aviation is by transitioning to SAF.” – American Airlines
● “SAF is proven, scalable, and the best tool we have to reduce our carbon emissions from flying.” – United Airlines
According to McKinsey & Co., SAF is the only viable near-term option to reduce emissions in aviation. Yet demand is expected to outpace supply by 2030 unless production capacity scales quickly.
XCF Global plans to leverage the technology stack and site layout of its New Rise Reno facility as a model for future production sites. The company has filed a utility patent for the modular design, which reduces the physical footprint required for construction and enables faster deployment across new locations.
The facility is divided into four key modules: feedstock receiving, pretreatment, hydrotreatment, and finished product offtake. Both the feedstock intake and product distribution modules are built with direct access to rail and truck transport, allowing materials to be unloaded and shipped without long-term storage.
This design reduces the need for large tank farms, improves logistics efficiency, and shortens construction timelines—making it a scalable blueprint for SAF expansion.
Highlights
● Rapidly Expanding SAF Market: The US Sustainable Aviation Fuel (SAF) market is projected to reach 3 billion gallons annually by 2030, driven by regulatory mandates and increasing demand for low-carbon aviation fuels.
● Significant Capacity Expansion: XCF plans to scale its production capacity from an initial ~38 million gallons per year to over ~160 million gallons annually by 2028, with a long-term goal to reach up to 1 billion gallons of blended SAF production capacity.
● Strategic Facility Acquisitions: In addition to the operating New Rise Reno, XCF has acquired and is developing additional sites—including a second plant adjacent to New Rise Reno, which will benefit from shared infrastructure to reduce build-out costs and timelines—as well as projects in Wilson, North Carolina, and Fort Myers, Florida, to build out a national SAF production network.
● First Public Pure-Play SAF Producer: Upon completion of its business combination with Focus Impact BH3 Acquisition Co., XCF Global is the only publicly traded company in the US focused on SAF production, distinguishing it from competitors that are primarily legacy crude oil refiners.
● Replicable Facility Design: XCF’s standardized and scalable facility design allows for rapid deployment across various locations, facilitating swift expansion to meet growing SAF demand.
● Industry Expertise: Led by CEO Mihir Dange, who brings over 20 years of experience in commodities trading and finance, the executive team possesses deep industry knowledge and a track record of successful project execution.
● Significant Emissions Reduction: SAF can reduce lifecycle carbon emissions by up to 80% compared to traditional jet fuel, contributing to the decarbonization of the aviation industry.
● Alignment with Global Initiatives: The company’s mission aligns with international efforts to combat climate change, including the US government’s Synthetic Aviation Fuel Grand Challenge.
WHAT IS SYNTHETIC AVIATION FUEL?
SAF can be made from a variety of non-food feedstocks via multiple technical pathways, each with different levels of sustainability
● SAF is synthetic kerosene derived from non-food feedstocks such as waste oils and fats, green and municipal waste and non-food crops
● SAF is able to recycle CO2 absorbed by biomass during its lifetime rather than injecting new carbon into the system, reducing emissions by up to 80%(1)
● SAF is a ‘drop-in’ fuel, easily integrating with existing aviation infrastructure
XCF Global distinguishes itself in the synthetic aviation fuel (SAF) sector through several strategic and operational advantages:
1. Pure-Play SAF Focus: SAFX is the only US-based public company dedicated to SAF production, positioning itself as a leader in this niche market.
2. Operational Production Facility: The company’s New Rise Renewables facility in Reno, Nevada, commenced commercial production in early 2025 and is currently completing ramp-up processes, with an annual capacity of ~38 million gallons.
3. Modular Plant Design: XCF employs a patent-pending modular design for its facilities, allowing for rapid deployment and scalability across various locations.
4. Strategic Partnerships: A long-term agreement with Phillips 66 ensures a stable supply of non-food feedstock and offtake of renewable fuels, providing financial stability and supply chain reliability.
5. Feedstock Flexibility: The company’s technology accommodates various non-food feedstocks, enhancing resilience against supply volatility and reducing carbon intensity scores.
6. Expansion Plans: XCF aims to increase its annual SAF production capacity to ~160 million gallons by 2028, with additional facilities planned in Nevada, Florida, and North Carolina.
7. Public Listing: Through a merger with Focus Impact BH3 Acquisition Co., XCF Global just became a publicly traded company, enhancing its visibility and access to capital markets.
XCF Global Begins Trading on Nasdaq Under Ticker Symbol “SAFX”
06/09/2025
Topic: Company Update
RENO, NV AND NEW YORK, NY / ACCESS Newswire / June 9, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Synthetic Aviation Fuel (“SAF”), announced that its Class A common stock will begin trading at market open today on the Nasdaq Capital Market under the ticker symbol “SAFX.” The announcement follows the closing of XCF’s business combination with Focus Impact BH3 Acquisition Company on June 6, 2025.
“We’re proud to begin our journey as a public company and to raise awareness to the growing need for low-carbon aviation solutions,” said Mihir Dange, Chief Executive Officer of XCF. “The public listing enables us to accelerate development of our SAF platform and expand production to meet the aviation sector’s growing demand for low-carbon fuel solutions. Our public debut aligns with a new era of growing demand and transformative opportunity – a mission that has never been more urgent.”
Highlights
● XCF Global’s New Rise Reno facility began commercial production of neat SAF in February 2025, with a nameplate production capacity of 38 million gallons of neat SAF per year
● First customer deliveries of neat SAF completed in March 2025, marking a major operational milestone
● Advancing a pipeline of production sites in Nevada, North Carolina, and Florida to expand SAF capacity and support long-term growth
Advisors
Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC, acted as exclusive financial advisor and joint capital markets advisor to XCF. Height Capital Markets served as joint capital markets advisor to XCF Global. BTIG, LLC acted as capital markets advisor to Focus Impact BH3. Stradley Ronon Stevens & Young, LLP and Kirkland & Ellis LLP served as legal counsel to XCF and Focus Impact BH3, respectively. Alliance Advisors Investor Relations served as investor relations and public relations advisor for the transaction.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF EIGHT THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY SAFX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
COVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025
Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to initiate in second half of 2025
Gedeptin® advancing into Phase 2 clinical trial of as treatment for first recurrent head and neck cancer in combination with immune checkpoint inhibitor
GeoVax reported cash balances of $7.4 million at March 31, 2025
GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA
We are coming off of another explosive week. One of our profiles from last week jumped over 50% on massive interest. These are exciting markets and it is a great environment for small caps right now.
We anticipate another busy and exciting week.
We want to bring back a company that we took a look at earlier this year. Over the next 4 sessions it went on to run roughly 25% on strong interest.
Pull up GOVX right away and put it at the top of your screen after you write it down.
Today this one got some MAJOR momentum and closed up 28% on huge momentum. GOVX is now well on the other side of the crititical $1 level. Is this the beginning of a short squeeze? GOVX has been sitting in a fairly tight channel since the beginning of April. Before today it had not closed outside the top of that channel since March.
When you look back at the year chart you are going to see a lot of that volatility that we love here at Insider.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune checkpoint inhibitor is planned to initiate during the first half of 2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.
GeoVax Responds to WHO’s Fourth Declaration of Mpox as a Global Public Health Emergency
GEO-MVA Provides Potential Opportunity to Expand Mpox Vaccine Supply Amid Growing U.S.and Global Clade 1 Threat
ATLANTA, GA – June 11, 2025 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a statement in response to the World Health Organization’s (WHO) fourth declaration of Mpox as a Public Health Emergency of International Concern (PHEIC). The WHO’s decision reflects the ongoing global spread of the highly virulent Clade 1 strain of the Mpox virus, which has prompted heightened international concern and a call to action for more robust vaccine strategies.
Mpox continues to pose a significant threat to global health, with WHO reporting rising case counts in endemic and non-endemic regions alike. In particular, Clade 1 Mpox – previously confined to Central Africa – is now appearing in Europe, Asia, and North America. In the United States, multiple confirmed Clade 1 cases have been reported across New York, California, Georgia, and New Hampshire. Additionally, Clade 1 viral particles have been detected in wastewater in North Carolina, California, Alabama and Iowa, suggesting silent transmission may be occurring even before symptomatic cases emerge.
U.S. and Global Reliance on a Single Supplier Threatens Response Capacity
Despite the urgency, the world remains dangerously dependent on a single manufacturer for the preferred Mpox vaccine, based on the Modified Vaccinia Ankara (MVA) platform. This presents significant risks to biosecurity, affordability, and equitable distribution. African nations alone have requested 20 million doses for 2025; global capacity is estimated at only 2-5 million doses annually.
GEO-MVA: America’s Strategic Vaccine Alternative
GeoVax is actively developing GEO-MVA, a U.S.-based MVA vaccine for Mpox and smallpox. GEO-MVA is engineered as an alternative to the existing global supply and has been recognized at global forums as a pivotal component of future pandemic resilience.
GeoVax has completed cGMP drug substance manufacturing of GEO-MVA, with fill/finish processes underway. Clinical vials are expected to be available in Q4 ’25, enabling clinical trials to begin in 2026.
GEO-MVA is also being developed using an advanced continuous avian cell line manufacturing process, intended to:
Increase production yield and scalability.
Eliminate reliance on pathogen-free chicken eggs.
Reduce cost and streamline use of existing manufacturing infrastructure.
Enable U.S.-based rapid deployment in future outbreaks.
“WHO’s latest declaration underscores that the Mpox crisis is not behind us – it is escalating,” said David Dodd, Chairman & CEO of GeoVax. “As Clade 1 spreads in the U.S. and globally, we must act now to expand domestic vaccine capacity. Single-source dependency threatens access during geopolitical or logistical disruptions. GEO-MVA offers a scalable, cost-effective, and onshore alternative that supports national security, global equity, and pandemic preparedness.”
Strengthening Biosecurity and Public Health Readiness
GeoVax is engaged with U.S. federal agencies to align GEO-MVA with government initiatives aimed at onshoring critical pharmaceutical manufacturing and strengthening national pandemic readiness. The company’s proposal under BARDA’s Rapid Response Partnership Vehicle (RRPV) was selected for award, pending funding, to scale MVA-based vaccine production using advanced U.S. biomanufacturing technologies.
GeoVax is calling on global and national policymakers to:
Accelerate regulatory pathways for GEO-MVA and next-generation MVA manufacturing.
Expand federal funding to ensure rapid scale-up and stockpiling.
Preserve early warning surveillance systems such as wastewater monitoring.
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
COVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025
Clinical evaluation of GEO-MVA, vaccine candidate for protection against Mpox and Smallpox, expected to initiate in second half of 2025
Gedeptin® advancing into Phase 2 clinical trial of as treatment for first recurrent head and neck cancer in combination with immune checkpoint inhibitor
ATLANTA, GA – May 1, 2025 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced its financial results and key operational accomplishments for the quarter ended March 31, 2025.
“Despite the recent and unexpected termination of our Project NextGen award by BARDA, our commitment to advancing GEO-CM04S1 remains unwavering. This next-generation, multi-antigen COVID-19 vaccine is highly differentiated and continues to show promise, particularly for the over 40 million immunocompromised individuals in the U.S. who remain vulnerable to current variants. Our ongoing Phase 2 trials, including studies in chronic lymphocytic leukemia patients and stem cell transplant recipients, are progressing well, with key data readouts anticipated in the first half of 2025,” stated David Dodd, GeoVax’s Chairman and CEO.
Dodd continued, “Concurrently, we are preparing to initiate the clinical evaluation of GEO-MVA during the second half 2025, while a Phase 2 trial of Gedeptin in combination with an immune checkpoint inhibitor for recurrent head and neck cancer is advancing towards trial initiation These efforts underscore GeoVax’s strategic focus on delivering innovative immunotherapies and vaccines that address critical unmet needs across oncology, infectious diseases and biodefense.”
Clinical Trial Progress and Operational Developments
GEO-CM04S1
GEO-CM04S1 continues to demonstrate potential as both a primary and booster vaccine, especially in immunocompromised patients. Key milestones anticipated during 2025 include:
Healthy Adult Booster Trial – Enrollment is complete, with data readout expected in the second quarter of 2025.
Chronic Lymphocytic Leukemia (CLL) Patient Study (Immunocompromised patient study) – Enrollment ongoing in Phase 2 study evaluating GEO-CM04S1 as a COVID-19 booster vaccine for immunocompromised patients; interim data resulted in continuation of the GEO-CM04S1 arm, whereas the Data Safety Review Board recommended early termination of the mRNA arm, which was subsequently implemented.
Stem Cell Transplant/CAR-T Trial (Immunocompromised patient study) – Enrollment and evaluation continue among hematological patients receiving stem cell transplantation or CAR-T therapy, comparing GEO-CM04S1 to mRNA COVID-19 vaccines.
GEO-CM04S1 is a multi-antigen COVID-19 vaccine, utilizing a synthetic-MVA platform, expressing both S and N antigens, offering the potential for broader, more durable protection than current mRNA vaccines.
Published peer-reviewed article in Vaccines (MDPI) – In April 2025, a peer-reviewed article titled “Preclinical Evaluation of a Multi-Antigen SARS-CoV-2 Vaccine Candidate GEO-CM02” was published in Vaccines (MDPI), which highlights the potential benefits of GeoVax’s multi-antigen COVID-19 vaccine approach and further validates the Company’s approach for developing GEO-CM04S1 utilizing the MVA platform. The publication supports the rationale for advancing next-generation COVID-19 vaccines capable of delivering broader, more durable immune responses.
GEO-CMO4S1 addresses a significant medical need worldwide reflected in an estimated market potential at $30B+.
Gedeptin®
Advancing into Phase 2 in Solid Tumors – GeoVax’s oncology program, utilizing the Gedeptin® technology, is planned to progress to a Phase 2 trial in combination with an immune checkpoint inhibitor for first recurrent head and neck cancer. Gedeptin has received Orphan Drug designation for use among advanced head & neck cancer patients. The Gedeptin technology provides potential for expansion into other solid tumors including triple-negative breast cancer, melanoma, and soft tissue sarcoma.
Gedeptin addresses a significant medical need worldwide reflected in an estimated market potential for use addressing Head & Neck cancer at $15B+.
GEO-MVA
Mpox and Smallpox Vaccine Platform Addressing Biosecurity and Global Vaccine Equity -GeoVax anticipates initiating clinical trials in 2025 for GEO-MVA, its Mpox/smallpox vaccine candidate. The Company has successfully produced cGMP clinical product and is focused on completing the vaccine vialing in support of initiating clinical evaluation during the second half of 2025. GEO-MVA positions GeoVax to offer a U.S.-developed alternative to foreign-sourced vaccines amid rising global biosecurity threats and constrained supply.
GEO-MVA addresses a significant medical need worldwide reflected in an estimated market potential at $10B+.
Vaccine Manufacturing Process Development
Scaling MVA for Global Reach – GeoVax is advancing continuous cell line manufacturing for MVA-based vaccines, offering a path to scalable, cost-effective production – including localized manufacturing for low- and middle-income countries. This innovation addresses critical gaps in vaccine self-sufficiency and supply resilience.
Corporate Updates
Announced plan to establish strategic presence in the United Kingdom to advance manufacturing partnerships, European collaborations with service providers and academic partners, technology licensing opportunities and scientific expertise.
Senthil Ranganathan, Ph.D., joined GeoVax on April 21, 2025, as Vice President, Technical Development & CMC Operations, reflecting significant progress in the Company focus on product authorization and commercialization activities.
First Quarter 2025 Financial Results
Net Loss: Net loss for the three months ended March 31, 2025, was $5.4 million, as compared to $5.9 million for the three months ended March 31, 2024.
Revenue: For the three months ended March 31, 2025, the Company reported $1.6 million of government contract revenues associated with the BARDA/RRPV Project NextGen award. There were no revenues reported during the comparable 2024 period.
R&D Expenses: Research and development expenses were $5.4 million for the three months ended March 31, 2025, compared to $4.4 million for the three months ended March 31, 2024, with the increase primarily due to costs associated with the BARDA/RRPV Project NextGen award and the Gedeptin and GEO-MVA programs.
G&A Expenses: General and administrative expenses were $1.7 million for the three months ended March 31, 2025, compared to $1.5 million for the three months ended March 31, 2024, with the increase primarily due to higher investor relations consulting costs and stock-based compensation expense.
Cash Position: GeoVax reported cash balances of $7.4 million at March 31, 2025, as compared to $5.5 million at December 31, 2024.
Summarized financial information is attached. Further information is included in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.
MVA TECHNOLOGY OVERVIEW
GeoVax’s vaccines are constructed to induce broader immunity through inclusion of multiple antigens into a single virus/vaccine platform. This is possible through the use of the company’s MVA vaccine platform, a large virus capable of incorporating multiple antigens into a vaccine platform.
Utilizing MVA, as a vaccine vector, allows for the targeting of multiple sites on a pathogen or cancer cell. Doing this is intended to result in a more robust and durable protective immune response. In addition, using MVA as a vaccine platform allows for the construction of vaccines which are capable of generating virus-like particles (VLPs) in the person receiving the vaccine.
The production of VLPs in the person being vaccinated is intended to mimic viral production that occurs in a natural infection, stimulating both the humoral (antibody) and cellular (T-cell) arms of the immune system to recognize, prevent, and control future infections.
MVA vectored vaccines can elicit durable (long-acting) immune responses while also possessing an excellent safety profile. MVA-VLP vaccines are designed to mimic authentic viruses in form but are not infectious or capable of replicating. As a result, VLPs can cause the body’s immune system to recognize and kill targeted infectious agents to prevent an infection or can be designed to target cancerous cells resulting in inhibited growth or destruction of tumors. VLPs can also train the immune system to recognize and kill virus-infected cells to control infection and reduce the length and severity of disease.
GEDEPTIN TECHNOLOGY OVERVIEW
A Phase 1/2 trial (NCT03754933), evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for injection and no curable treatment options recently completed enrollment at the Stanford University Cancer Institute, the Emory University Winship Cancer Institute, and the Thomas Jefferson University Sidney Kimmel Cancer Center.
The trial design involved repeat administration using Gedeptin followed by systemic fludarabine (prodrug). Expansion towards a larger, Phase 2 patient trial is anticipated. The FDA has granted Gedeptin orphan drug status for the intra-tumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities. Also, the initial Phase 1/2 clinical study was funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program.
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
Preclinical Studies Demonstrate Durable Protection Against SARS-CoV-2 Variants, Including Omicron XBB.1.5, Driven by T-Cell Responses
ATLANTA, GA – June 9, 2025 (NEWMEDIAWIRE) – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and multi-antigen vaccines against infectious diseases and solid tumors, today recapped two scientific poster presentations delivered at the Keystone Symposia on Vaccinology: Horizons Across Disease, Demography and Technology, held June 4-7, 2025, in Washington, D.C.
The presentations, titled MVA-Vectored Multi-Antigen COVID-19 Vaccines Induce Protective Immunity Against SARS-CoV-2 Variants Spanning Alpha to Omicron in Preclinical Animal Models, and GEO-CM04S1 Vaccine Candidate Maintains Potent Cross-Reactivity Against Original SARS-CoV-2 B.1 and Omicron Subvariant XBB.1.5, were delivered by Drs. Pratima Kumari and Amany Elsharkawy, respectively, members of GeoVax’s scientific team and its collaborators, during the June 5 and June 6 poster sessions. The presentations spotlight the Company’s Modified Vaccinia Ankara (MVA)-vectored COVID-19 vaccine candidates, GEO-CM04S1 and GEO-CM02, and their ability to induce durable, cross-reactive immunity against SARS-CoV-2 variants in preclinical animal models. These studies underscore the immunologic breadth, durability, and cross-variant protection of GeoVax’s multi-antigen design strategy, especially important for addressing variant evasion and suboptimal immune response in vulnerable patient populations.
Key Findings from Studies
GEO-CM02 Study – Poster #1050 – Presenter: Dr. Pratima Kumari, GeoVax Scientist
This presentation detailed findings for GEO-CM02, a multi-antigen MVA-based vaccine expressing the spike (S), membrane (M), and envelope (E) proteins.
In hACE2 mouse models, a single dose provided complete protection against both the original Wuhan strain and the Omicron BA.1 variant.
Two-dose regimens generated high neutralizing antibody levels, reduced viral loads in lung and brain tissues, and lowered inflammatory markers- indicating enhanced immune memory.
Notably, early protection was achieved prior to detectable neutralizing antibodies, further supporting the role of innate and cellular immune responses in viral control. This underscores the value of the multi-antigen MVA-based vaccine platform, particularly as the virus continues to mutate.
GEO-CM04S1 Study – Poster #2047 – Presenter: Dr. Amany Elsharkawy, Georgia State University Scientist
This study evaluated the immunogenicity and protective efficacy of GEO-CM04S1, an MVA-vectored vaccine co-expressing spike (S) and nucleocapsid (N) proteins, in a K18-hACE2 mouse model. Mice were challenged intranasally with either the original B.1 strain or the Omicron XBB.1.5 subvariant.
GEO-CM04S1 conferred full protection against clinical disease, lung injury, and inflammation in both viral challenge models.
Despite the absence of detectable neutralizing antibodies against XBB.1.5, vaccinated animals were fully protected, suggesting antibody-independent protection.
Immune cell depletion studies revealed that CD4+ T cells, not B cells or CD8+ T cells, were critical for protection, highlighting the vaccine’s ability to drive T cell-mediated immunity across variants.
“These experimental findings document the value of inducing broadly specific immune responses to protect against evolving SARS-CoV-2 variants,” said Mark Newman, PhD, Chief Scientific Officer of GeoVax. “We believe the use of multi-antigen vaccines could provide significant benefit by limiting the need to continually update COVID vaccines and by limiting the need for yearly booster doses.”
GeoVax’s MVA vaccine platform is designed to address gaps in pandemic preparedness and public health resilience, with lead vaccine candidate GEO-CM04S1 currently being evaluated in multiple Phase 2 clinical trials for COVID-19.
About GEO-CM04S1
GEO-CM04S1 is a synthetic next-generation, multi-antigen MVA-vectored COVID-19 vaccine co-expressing spike (S) and nucleocapsid (N) antigens, designed to induce both broad antibody and T-cell responses. It is being evaluated in three ongoing Phase 2 clinical trials:
A primary vaccine for immunocompromised individuals (e.g., post-transplant, CAR-T, or hematologic cancers)
A booster for patients with chronic lymphocytic leukemia (CLL)
A booster for healthy adults previously immunized with mRNA vaccines
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY GOVX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.